false2021Q3--12-310001618835☐http://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberP5YP5YP5YP2YP10YP4YP3Y000016188352021-01-012021-09-300001618835us-gaap:CommonStockMember2021-01-012021-09-300001618835us-gaap:PreferredStockMember2021-01-012021-09-30xbrli:shares00016188352021-10-31iso4217:USD00016188352021-09-3000016188352020-12-31iso4217:USDxbrli:shares00016188352021-07-012021-09-3000016188352020-01-012020-09-3000016188352020-07-012020-09-300001618835us-gaap:CommonStockMember2020-12-310001618835us-gaap:AdditionalPaidInCapitalMember2020-12-310001618835us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001618835us-gaap:RetainedEarningsMember2020-12-310001618835evfm:PublicOfferingMemberus-gaap:CommonStockMember2021-01-012021-03-310001618835evfm:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001618835evfm:PublicOfferingMember2021-01-012021-03-310001618835us-gaap:CommonStockMember2021-01-012021-03-310001618835us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100016188352021-01-012021-03-310001618835us-gaap:RetainedEarningsMember2021-01-012021-03-310001618835us-gaap:CommonStockMember2021-03-310001618835us-gaap:AdditionalPaidInCapitalMember2021-03-310001618835us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001618835us-gaap:RetainedEarningsMember2021-03-3100016188352021-03-310001618835evfm:PublicOfferingMemberus-gaap:CommonStockMember2021-04-012021-06-300001618835evfm:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001618835evfm:PublicOfferingMember2021-04-012021-06-300001618835us-gaap:WarrantMemberus-gaap:CommonStockMember2021-04-012021-06-300001618835us-gaap:WarrantMemberus-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001618835us-gaap:WarrantMember2021-04-012021-06-300001618835us-gaap:CommonStockMember2021-04-012021-06-300001618835us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000016188352021-04-012021-06-300001618835us-gaap:RetainedEarningsMember2021-04-012021-06-300001618835us-gaap:CommonStockMember2021-06-300001618835us-gaap:AdditionalPaidInCapitalMember2021-06-300001618835us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001618835us-gaap:RetainedEarningsMember2021-06-3000016188352021-06-300001618835us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001618835us-gaap:WarrantMemberus-gaap:CommonStockMember2021-07-012021-09-300001618835us-gaap:WarrantMemberus-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001618835us-gaap:WarrantMember2021-07-012021-09-300001618835us-gaap:CommonStockMember2021-07-012021-09-300001618835us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001618835us-gaap:RetainedEarningsMember2021-07-012021-09-300001618835us-gaap:CommonStockMember2021-09-300001618835us-gaap:AdditionalPaidInCapitalMember2021-09-300001618835us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001618835us-gaap:RetainedEarningsMember2021-09-300001618835us-gaap:CommonStockMember2019-12-310001618835us-gaap:AdditionalPaidInCapitalMember2019-12-310001618835us-gaap:RetainedEarningsMember2019-12-3100016188352019-12-310001618835us-gaap:CommonStockMemberevfm:AtTheMarketATMMember2020-01-012020-03-310001618835us-gaap:AdditionalPaidInCapitalMemberevfm:AtTheMarketATMMember2020-01-012020-03-310001618835evfm:AtTheMarketATMMember2020-01-012020-03-310001618835us-gaap:CommonStockMember2020-01-012020-03-310001618835us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100016188352020-01-012020-03-310001618835us-gaap:RetainedEarningsMember2020-01-012020-03-310001618835us-gaap:CommonStockMember2020-03-310001618835us-gaap:AdditionalPaidInCapitalMember2020-03-310001618835us-gaap:RetainedEarningsMember2020-03-3100016188352020-03-310001618835evfm:PublicOfferingMemberus-gaap:CommonStockMember2020-04-012020-06-300001618835evfm:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001618835evfm:PublicOfferingMember2020-04-012020-06-300001618835us-gaap:CommonStockMemberevfm:AtTheMarketATMMember2020-04-012020-06-300001618835us-gaap:AdditionalPaidInCapitalMemberevfm:AtTheMarketATMMember2020-04-012020-06-300001618835evfm:AtTheMarketATMMember2020-04-012020-06-300001618835us-gaap:CommonStockMember2020-04-012020-06-300001618835us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000016188352020-04-012020-06-300001618835us-gaap:WarrantMemberus-gaap:CommonStockMember2020-04-012020-06-300001618835us-gaap:WarrantMemberus-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001618835us-gaap:WarrantMember2020-04-012020-06-300001618835us-gaap:RetainedEarningsMember2020-04-012020-06-300001618835us-gaap:CommonStockMember2020-06-300001618835us-gaap:AdditionalPaidInCapitalMember2020-06-300001618835us-gaap:RetainedEarningsMember2020-06-3000016188352020-06-300001618835us-gaap:CommonStockMember2020-07-012020-09-300001618835us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001618835us-gaap:RetainedEarningsMember2020-07-012020-09-300001618835us-gaap:CommonStockMember2020-09-300001618835us-gaap:AdditionalPaidInCapitalMember2020-09-300001618835us-gaap:RetainedEarningsMember2020-09-3000016188352020-09-3000016188352021-01-012021-06-300001618835us-gaap:ConvertibleNotesPayableMember2020-04-012020-12-3100016188352020-06-012020-06-300001618835us-gaap:IPOMember2020-01-012020-12-31evfm:segmentxbrli:pure0001618835evfm:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001618835evfm:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001618835evfm:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001618835evfm:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001618835us-gaap:AccountsReceivableMemberevfm:ThreeLargestCustomersMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001618835us-gaap:AccountsReceivableMemberevfm:ThreeLargestCustomersMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001618835us-gaap:BuildingAndBuildingImprovementsMemberus-gaap:LetterOfCreditMember2021-09-300001618835us-gaap:LetterOfCreditMemberus-gaap:VehiclesMember2021-09-300001618835us-gaap:ConvertibleNotesPayableMember2020-12-3100016188352020-10-012020-12-310001618835us-gaap:OtherNoncurrentAssetsMember2021-09-300001618835us-gaap:OtherNoncurrentAssetsMember2020-09-300001618835evfm:UnvestedRestrictedStockAwardsSubjectToRepurchaseMember2021-01-012021-09-300001618835evfm:UnvestedRestrictedStockAwardsSubjectToRepurchaseMember2021-07-012021-09-300001618835evfm:UnvestedRestrictedStockAwardsSubjectToRepurchaseMember2020-07-012020-09-300001618835evfm:UnvestedRestrictedStockAwardsSubjectToRepurchaseMember2020-01-012020-09-300001618835us-gaap:EmployeeStockMember2021-07-012021-09-300001618835us-gaap:EmployeeStockMember2021-01-012021-09-300001618835us-gaap:EmployeeStockMember2020-07-012020-09-300001618835us-gaap:EmployeeStockMember2020-01-012020-09-300001618835us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001618835us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001618835us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001618835us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001618835us-gaap:WarrantMember2021-01-012021-09-300001618835us-gaap:WarrantMember2021-07-012021-09-300001618835us-gaap:WarrantMember2020-07-012020-09-300001618835us-gaap:WarrantMember2020-01-012020-09-300001618835srt:MinimumMember2021-01-012021-09-300001618835srt:MaximumMember2021-01-012021-09-300001618835us-gaap:ConvertibleNotesPayableMember2020-04-2300016188352020-04-242020-04-240001618835evfm:FirstClosingWarrantsMember2020-04-2400016188352020-04-2500016188352020-06-092020-06-090001618835evfm:SecondClosingWarrantsMember2020-06-090001618835us-gaap:ConvertibleNotesPayableMember2020-04-232020-04-230001618835us-gaap:ConvertibleNotesPayableMember2021-07-012021-09-300001618835us-gaap:ConvertibleNotesPayableMember2021-01-012021-09-300001618835us-gaap:ConvertibleNotesPayableMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2020-04-232020-04-230001618835us-gaap:ConvertibleNotesPayableMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2020-04-232020-04-230001618835us-gaap:ConvertibleNotesPayableMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2020-04-232020-04-2300016188352020-04-2400016188352020-06-0500016188352020-06-052020-06-0500016188352020-06-182020-06-180001618835us-gaap:ConvertibleNotesPayableMemberevfm:AdjuvantNotesMember2020-10-140001618835us-gaap:ConvertibleNotesPayableMemberevfm:AdjuvantNotesMember2020-10-142020-10-140001618835us-gaap:ConvertibleNotesPayableMemberevfm:AdjuvantNotesMember2021-07-012021-09-300001618835us-gaap:ConvertibleNotesPayableMemberevfm:AdjuvantNotesMember2021-01-012021-09-300001618835us-gaap:ConvertibleNotesPayableMemberevfm:AdjuvantNotesMembersrt:MinimumMember2020-10-142020-10-140001618835us-gaap:ConvertibleNotesPayableMembersrt:MaximumMemberevfm:AdjuvantNotesMember2020-10-142020-10-140001618835us-gaap:ConvertibleNotesPayableMemberevfm:AdjuvantNotesMember2021-09-300001618835evfm:SellingAndMarketingRelatedCostsMember2021-09-300001618835evfm:SellingAndMarketingRelatedCostsMember2020-12-310001618835evfm:InsuranceMember2021-09-300001618835evfm:InsuranceMember2020-12-310001618835evfm:PrepaidClinicalTrialRelatedCostsMember2021-09-300001618835evfm:PrepaidClinicalTrialRelatedCostsMember2020-12-310001618835evfm:PrepaidsSubscriptionsForITPlatformsMember2021-09-300001618835evfm:PrepaidsSubscriptionsForITPlatformsMember2020-12-310001618835evfm:PrepaidManufacturingCostsMember2021-09-300001618835evfm:PrepaidManufacturingCostsMember2020-12-310001618835evfm:FlexNoteReceivableMember2021-09-300001618835evfm:FlexNoteReceivableMember2020-12-310001618835us-gaap:OtherCurrentAssetsMember2021-09-300001618835us-gaap:OtherCurrentAssetsMember2020-12-3100016188352016-07-3100016188352016-07-012016-07-310001618835us-gaap:EquipmentMember2021-01-012021-09-300001618835us-gaap:EquipmentMember2021-09-300001618835us-gaap:EquipmentMember2020-12-310001618835evfm:ComputerEquipmentAndSoftwareMember2021-01-012021-09-300001618835evfm:ComputerEquipmentAndSoftwareMember2021-09-300001618835evfm:ComputerEquipmentAndSoftwareMember2020-12-310001618835us-gaap:FurnitureAndFixturesMember2021-01-012021-09-300001618835us-gaap:FurnitureAndFixturesMember2021-09-300001618835us-gaap:FurnitureAndFixturesMember2020-12-310001618835srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2021-01-012021-09-300001618835us-gaap:LeaseholdImprovementsMember2021-09-300001618835us-gaap:LeaseholdImprovementsMember2020-12-310001618835us-gaap:ConstructionInProgressMember2021-09-300001618835us-gaap:ConstructionInProgressMember2020-12-310001618835us-gaap:MoneyMarketFundsMember2021-09-300001618835us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-09-300001618835us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2021-09-300001618835us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-09-300001618835us-gaap:FairValueInputsLevel1Member2021-09-300001618835us-gaap:FairValueInputsLevel2Member2021-09-300001618835us-gaap:FairValueInputsLevel3Member2021-09-300001618835us-gaap:MoneyMarketFundsMember2020-12-310001618835us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001618835us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2020-12-310001618835us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001618835us-gaap:FixedIncomeSecuritiesMemberus-gaap:CashAndCashEquivalentsMember2020-12-310001618835us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:CashAndCashEquivalentsMember2020-12-310001618835us-gaap:FixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2020-12-310001618835us-gaap:FixedIncomeSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001618835evfm:FlexNoteReceivableMemberus-gaap:FairValueInputsLevel1Member2020-12-310001618835evfm:FlexNoteReceivableMemberus-gaap:FairValueInputsLevel2Member2020-12-310001618835evfm:FlexNoteReceivableMemberus-gaap:FairValueInputsLevel3Member2020-12-310001618835us-gaap:FairValueInputsLevel1Member2020-12-310001618835us-gaap:FairValueInputsLevel2Member2020-12-310001618835us-gaap:FairValueInputsLevel3Member2020-12-310001618835us-gaap:ConvertibleNotesPayableMember2020-01-012020-12-310001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2021-06-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-06-300001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-06-300001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2021-07-012021-09-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-07-012021-09-300001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-07-012021-09-300001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2021-09-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-09-300001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-09-300001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2020-12-310001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-12-310001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-12-310001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-09-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-09-300001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-09-300001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2020-06-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-06-300001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-06-300001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2020-07-012020-09-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-07-012020-09-300001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-07-012020-09-300001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2020-09-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-09-300001618835us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-09-300001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2019-12-310001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2019-12-310001618835us-gaap:WarrantMemberevfm:BakerFirstClosingWarrantsMemberus-gaap:FairValueInputsLevel3Member2019-12-310001618835evfm:PurchaseRightsLiabilityMemberus-gaap:FairValueInputsLevel3Memberevfm:BakerPurchaseRightsMember2019-12-310001618835us-gaap:WarrantMemberevfm:BakerSecondClosingWarrantsMemberus-gaap:FairValueInputsLevel3Member2019-12-310001618835evfm:DebtWarrantsAndPurchaseRightsLiabilityMemberus-gaap:FairValueInputsLevel3Member2019-12-310001618835us-gaap:LongTermDebtMemberevfm:BakersFirstClosingNoteMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-300001618835evfm:BakersSecondClosingNotesMemberus-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-300001618835us-gaap:WarrantMemberevfm:BakerFirstClosingWarrantsMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-300001618835evfm:PurchaseRightsLiabilityMemberus-gaap:FairValueInputsLevel3Memberevfm:BakerPurchaseRightsMember2020-01-012020-09-300001618835us-gaap:WarrantMemberevfm:BakerSecondClosingWarrantsMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-300001618835evfm:DebtWarrantsAndPurchaseRightsLiabilityMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-300001618835us-gaap:WarrantMemberevfm:BakerFirstClosingWarrantsMemberus-gaap:FairValueInputsLevel3Member2020-09-300001618835evfm:PurchaseRightsLiabilityMemberus-gaap:FairValueInputsLevel3Memberevfm:BakerPurchaseRightsMember2020-09-300001618835us-gaap:WarrantMemberevfm:BakerSecondClosingWarrantsMemberus-gaap:FairValueInputsLevel3Member2020-09-300001618835evfm:DebtWarrantsAndPurchaseRightsLiabilityMemberus-gaap:FairValueInputsLevel3Member2020-09-300001618835evfm:BakerFirstClosingWarrantsMemberevfm:MeasurementInputExpectedVolatilityMember2020-09-300001618835evfm:BakerFirstClosingWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-09-300001618835evfm:BakerFirstClosingWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-09-300001618835evfm:BakerFirstClosingWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2020-09-3000016188352020-04-230001618835evfm:BakerWarrantsMember2021-09-300001618835evfm:LeaseContractTermOneMember2019-12-310001618835evfm:LeaseContractTermTwoMember2019-12-31evfm:vehicle0001618835evfm:SecuritiesDepositMemberus-gaap:VehiclesMember2021-09-300001618835evfm:SecuritiesDepositMemberus-gaap:VehiclesMember2020-12-31utr:sqft00016188352019-10-030001618835us-gaap:LetterOfCreditMember2019-10-0300016188352020-04-140001618835us-gaap:LetterOfCreditMember2020-04-140001618835us-gaap:BuildingAndBuildingImprovementsMemberevfm:SecuritiesDepositMember2021-09-300001618835us-gaap:BuildingAndBuildingImprovementsMemberevfm:SecuritiesDepositMember2020-12-310001618835us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001618835us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001618835us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001618835us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001618835us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300001618835us-gaap:SellingAndMarketingExpenseMember2020-07-012020-09-300001618835us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300001618835us-gaap:SellingAndMarketingExpenseMember2020-01-012020-09-300001618835us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001618835us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001618835us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001618835us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-30evfm:claim0001618835evfm:RushUniversityMemberus-gaap:RoyaltyAgreementTermsMember2021-01-012021-01-010001618835evfm:RushUniversityMembersrt:MaximumMember2021-01-010001618835evfm:RushUniversityMemberus-gaap:RoyaltyAgreementTermsMember2021-07-012021-09-300001618835evfm:RushUniversityMemberus-gaap:RoyaltyAgreementTermsMember2021-01-012021-09-300001618835evfm:ConsultingAgreement2019Memberevfm:ThomasLynchMember2019-04-012019-04-010001618835evfm:ConsultingAgreement2019Memberevfm:SupervisoryBoardMemberevfm:ThomasLynchMember2019-04-012019-04-010001618835evfm:AmendedAndRestated2014PlanMembersrt:BoardOfDirectorsChairmanMemberus-gaap:RestrictedStockUnitsRSUMember2019-04-012019-04-0100016188352019-04-012019-04-010001618835evfm:ConsultingAgreementsMemberevfm:ThomasLynchMember2021-07-012021-09-300001618835evfm:ConsultingAgreementsMemberevfm:ThomasLynchMember2020-07-012020-09-300001618835evfm:ConsultingAgreementsMemberevfm:ThomasLynchMember2021-01-012021-09-300001618835evfm:ConsultingAgreementsMemberevfm:ThomasLynchMember2020-01-012020-09-300001618835evfm:SecurityPurchaseAgreementWarrantsMember2020-06-300001618835evfm:PublicOfferingMemberus-gaap:WarrantMember2021-05-310001618835us-gaap:WarrantMember2021-06-012021-06-300001618835us-gaap:WarrantMember2021-07-012021-07-310001618835evfm:CommonWarrantsMember2012-03-300001618835evfm:CommonWarrantsMember2012-08-170001618835evfm:CommonWarrantsMember2014-06-110001618835evfm:CommonWarrantsMember2018-05-240001618835evfm:CommonWarrantsMember2018-06-260001618835evfm:CommonWarrantsMember2019-04-110001618835evfm:CommonWarrantsMember2019-06-100001618835evfm:CommonWarrantsMember2020-04-240001618835evfm:CommonWarrantsMember2020-06-090001618835evfm:CommonWarrantsMember2021-05-200001618835evfm:SeriesB1ConvertiblePreferredStockMemberevfm:RegisteredDirectOfferingMemberus-gaap:SubsequentEventMember2021-10-122021-10-120001618835evfm:SeriesB1ConvertiblePreferredStockMemberevfm:RegisteredDirectOfferingMemberus-gaap:SubsequentEventMember2021-10-120001618835evfm:SeriesB1ConvertiblePreferredStockMemberevfm:RegisteredDirectOfferingMemberus-gaap:SubsequentEventMembersrt:MinimumMember2021-10-12evfm:trading_day0001618835evfm:RegisteredDirectOfferingMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMember2021-10-122021-10-120001618835evfm:RegisteredDirectOfferingMemberevfm:SeriesB2ConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2021-10-262021-10-260001618835evfm:RegisteredDirectOfferingMemberevfm:SeriesB2ConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2021-10-260001618835evfm:RegisteredDirectOfferingMemberevfm:SeriesB2ConvertiblePreferredStockMemberus-gaap:SubsequentEventMembersrt:MinimumMember2021-10-2600016188352018-01-170001618835us-gaap:PreferredStockMember2018-01-170001618835evfm:PublicOfferingMember2020-06-052020-06-050001618835evfm:PublicOfferingMember2020-06-050001618835us-gaap:OverAllotmentOptionMember2020-06-102020-06-100001618835evfm:March2021PublicOfferingMember2021-03-292021-03-290001618835evfm:March2021PublicOfferingMember2021-03-290001618835us-gaap:OverAllotmentOptionMember2021-04-062021-04-060001618835evfm:May2021PublicOfferingMember2021-05-202021-05-200001618835evfm:May2021PublicOfferingMember2021-05-200001618835us-gaap:OverAllotmentOptionMember2021-05-202021-05-200001618835us-gaap:OverAllotmentOptionMember2021-05-200001618835us-gaap:OverAllotmentOptionMember2021-05-212021-05-210001618835evfm:PiperSandlerCo.Memberevfm:AtTheMarketATMMember2019-11-300001618835evfm:PiperSandlerCo.Memberevfm:AtTheMarketATMMember2020-01-012020-09-300001618835evfm:PiperSandlerCo.Memberevfm:AtTheMarketATMMember2019-12-310001618835us-gaap:EmployeeStockOptionMember2021-09-300001618835evfm:EmployeeStockPurchasePlan2019Member2021-09-300001618835evfm:AmendedAndRestated2014PlanMember2021-09-300001618835evfm:InducementPlanMember2021-09-300001618835evfm:TwoThousandTwelveEquityIncentivePlanMember2021-01-012021-09-300001618835evfm:TwoThousandTwelveEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-09-300001618835evfm:TwoThousandTwelveEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-09-300001618835evfm:AmendedAndRestated2014PlanMember2014-09-150001618835evfm:AmendedAndRestated2014PlanMember2019-02-260001618835evfm:AmendedAndRestated2014PlanMember2020-02-250001618835evfm:AmendedAndRestated2014PlanMember2019-02-262019-02-260001618835evfm:AmendedAndRestated2014PlanMember2021-01-010001618835evfm:InducementPlanMember2018-07-240001618835evfm:InducementPlanMember2020-02-250001618835us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001618835us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001618835us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001618835us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001618835evfm:ExecutiveManagementTeamAndCertainNonExecutiveEmployeesMemberevfm:AmendedAndRestated2014PlanMemberus-gaap:RestrictedStockMember2021-01-012021-09-300001618835evfm:ExecutiveManagementTeamAndCertainNonExecutiveEmployeesMemberevfm:AmendedAndRestated2014PlanMemberus-gaap:RestrictedStockMember2020-01-012020-09-300001618835srt:ManagementMemberevfm:AmendedAndRestated2014PlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockMember2021-01-012021-03-310001618835evfm:PerformanceBasedRestrictedStockAwardsMember2021-07-012021-09-300001618835evfm:PerformanceBasedRestrictedStockAwardsMember2021-01-012021-09-300001618835evfm:RestrictedStockAndRestrictedStockUnitsMember2021-01-012021-09-300001618835evfm:RestrictedStockAndRestrictedStockUnitsMember2020-07-012020-09-300001618835evfm:RestrictedStockAndRestrictedStockUnitsMember2020-01-012020-09-300001618835evfm:AmendedAndRestated2014PlanMemberus-gaap:RestrictedStockMember2021-09-300001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2019-05-070001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2019-05-072019-05-070001618835evfm:EmployeeStockPurchasePlan2019Member2021-01-010001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMembersrt:MinimumMember2021-01-012021-09-300001618835srt:MaximumMemberevfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2021-01-012021-09-300001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2021-01-012021-09-300001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2021-09-300001618835evfm:EmployeeStockPurchasePlan2019Member2021-07-012021-09-300001618835evfm:EmployeeStockPurchasePlan2019Member2020-07-012020-09-300001618835evfm:EmployeeStockPurchasePlan2019Member2021-01-012021-09-300001618835evfm:EmployeeStockPurchasePlan2019Member2020-01-012020-09-300001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2021-07-012021-09-300001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2020-01-012020-09-300001618835evfm:EmployeeStockPurchasePlan2019Memberus-gaap:EmployeeStockMember2020-07-012020-09-300001618835evfm:RestrictedStockAndRestrictedStockUnitsMember2021-07-012021-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________________________________
 
FORM 10-Q
  ____________________________________________________
 (Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to                
Commission File Number: 001-36754
  _____________________________________________________
  EVOFEM BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
 ___________________________________________________ 
Delaware
(State or other jurisdiction
of incorporation)
20-8527075
(IRS Employer
Identification No.)
12400 High Bluff Drive, Suite 600
San Diego, CA
(Address of Principal Executive Offices)
92130
(Zip Code)
Registrant’s telephone number, including area code: (858) 550-1900
Not applicable.
(Former name or former address, if changed since last report.)
 ____________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share EVFM
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
Series A Preferred Stock Purchase Rights, par value $0.0001 per share N/A
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

The number of shares of the registrant’s common stock, $0.0001 par value per share, outstanding as of October 31, 2021 was 163,144,964.

Table of Contents
Table of Contents
Page
1
PART I.
Item 1.
3
3
4
5
6
8
9
Item 2.
26
Item 3.
38
Item 4.
38
PART II.
Item 1.
39
Item 1A.
39
Item 2.
41
Item 3.
41
Item 4.
41
Item 5.
42
Item 6.
43
44


Table of Contents
FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q (Quarterly Report), contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements, other than statements of historical facts, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements include, among other things, statements about:

•our ability to raise additional capital to fund our operations;
•our ability to achieve and sustain profitability;
•our estimates regarding our future performance, including without limitation, any estimates of potential future revenues;
•estimates regarding market size;
•estimates regarding health care providers’ (HCPs) recommendations of Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel (Phexxi) to patients;
•the rate and degree of market acceptance of Phexxi;
•our ability to successfully commercialize Phexxi and continue to develop our sales and marketing capabilities;
•our estimates regarding the effectiveness of our marketing campaigns;
•our strategic plans for our business, including the commercialization of Phexxi;
•our estimates regarding expenses, revenues, financial performance and capital requirements, including the length of time our capital resources will sustain our operations;
•our ability to continue as a going concern;
•the impacts of the ongoing pandemic related to a novel strain of a virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus), which causes coronavirus disease 2019 (COVID-19), including, without limitation, its impact on our business and the commercialization of Phexxi;
•the potential for changes to current regulatory mandates requiring health insurance plans to cover United States (U.S.) Food and Drug Administration (FDA)-cleared or -approved contraceptive products without cost sharing;
•our ability to obtain or maintain third-party payer coverage and adequate reimbursement, and our reliance on the willingness of patients to pay out-of-pocket for Phexxi absent full or partial third-party payer reimbursement;
•our ability to obtain the necessary regulatory approvals to market and commercialize EVO100 vaginal gel (EVO100) for prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women, and any other product candidate we may seek to develop;
•the success, cost and timing of our clinical trials;
•our top-line or initial clinical trial data, which are subject to adjustment and revision;
•our ability to protect and defend our intellectual property position and our reliance on third party licensors;
•our ability to obtain additional patent protection for our product and product candidates;
•our dependence on third parties in the conduct of our clinical trials and for the manufacture of Phexxi and our product candidates;
•our ability to expand our organization to accommodate potential growth; and
•our ability to retain and attract key personnel.

To date, only one of our products, Phexxi vaginal gel, has been approved by the FDA for marketing in the United States. Our other current product candidates are investigational and have not been submitted to or approved by the FDA, and neither Phexxi nor our other product candidates have been approved by the European Medicines Agency or any other regulatory authority anywhere else in the world. This Quarterly Report also contains estimates and other statistical data made by independent parties and by us relating to market opportunity, growth and other data about our industry. These data and estimates involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that these statements are based on our projections of the future that are subject to known and unknown risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements, to differ. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. You should read this Quarterly Report and the documents that we have filed as exhibits to this Quarterly Report and incorporated by reference herein completely and with the understanding that our actual results may be materially different from the plans, intentions and expectations disclosed in the
1
Table of Contents
forward-looking statements we make. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

Unless the context requires otherwise, references in this Quarterly Report to “Evofem,” “Company,” “we,” “us” and “our” refer to Evofem Biosciences, Inc. and our subsidiaries.


2
Table of Contents

PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
  
(Unaudited)
(In thousands, except par value and share data)
  September 30, 2021 December 31, 2020
Assets
Current assets:
Cash and cash equivalents $ 14,856  $ 48,892 
Restricted cash 9,384  22,559 
Trade accounts receivable, net
4,031  1,067 
Inventories 9,947  7,162 
Prepaid and other current assets 16,685  18,050 
Total current assets 54,903  97,730 
Property and equipment, net 5,769  4,334 
Operating lease right-of-use assets 5,764  6,856 
Other noncurrent assets 991  1,048 
Total assets $ 67,427  $ 109,968 
Liabilities and stockholders’ equity (deficit)
Current liabilities:
Accounts payable $ 6,788  $ 10,641 
Convertible notes payable (Note 5) 68,724  52,409 
Accrued expenses 9,022  4,476 
Accrued compensation 5,253  6,514 
        Operating lease liabilities – current
2,418  2,290 
Other current liabilities 2,482  953 
Total current liabilities 94,687  77,283 
Operating lease liabilities – noncurrent
4,774  6,030 
Long-term convertible notes payable (Note 5) 26,696  25,211 
Other noncurrent liabilities 97  97 
Total liabilities 126,254  108,621 
Commitments and contingencies (Note 8)
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding
—  — 
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 300,000,000 shares authorized; 155,208,456 and 81,351,533 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively;
16  8 
Additional paid-in capital 745,194  656,827 
Accumulated other comprehensive income 5,089  — 
Accumulated deficit (809,126) (655,488)
Total stockholders’ equity (deficit) (58,827) 1,347 
Total liabilities and stockholders’ equity (deficit) $ 67,427  $ 109,968 

See accompanying notes to the condensed consolidated financial statements (unaudited).
3
Table of Contents
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share data)
 
Three Months Ended September 30, Nine Months Ended September 30,
  2021 2020 2021 2020
Product sales, net $ 1,712  $ 278  $ 4,674  $ 278 
Operating expenses:
Cost of goods sold 955  317  2,300  317 
Research and development 8,701  4,217  24,470  11,104 
Selling and marketing 30,468  14,700  88,230  32,553 
General and administrative 4,957  7,200  19,057  24,077 
Total operating expenses 45,081  26,434  134,057  68,051 
Loss from operations (43,369) (26,156) (129,383) (67,773)
Other income (expense):
Interest income 3  21  14  152 
Other expense (1,190) (657) (3,521) (1,010)
Loss on issuance of financial instruments —  —  —  (64,049)
Change in fair value of financial instruments (29,505) (3,105) (20,737) 30,971 
Total other expense, net (30,692) (3,741) (24,244) (33,936)
Loss before income tax (74,061) (29,897) (153,627) (101,709)
Income tax expense —  (2) (11) (2)
Net loss $ (74,061) $ (29,899) $ (153,638) $ (101,711)
Net loss per share, basic and diluted $ (0.48) $ (0.37) $ (1.27) $ (1.63)
Weighted-average shares used to compute net loss per share, basic and diluted 154,265,434  81,206,101  120,691,057  62,434,949 
See accompanying notes to condensed consolidated financial statements (unaudited).
4
Table of Contents
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE OPERATIONS
(Unaudited)
(In thousands, except share and per share data)
 
Three Months Ended September 30, Nine Months Ended September 30,
  2021 2020 2021 2020
Net loss $ (74,061) $ (29,899) $ (153,638) $ (101,711)
Other comprehensive income:
Change in fair value of financial instruments attributed to credit risk change 5,089  —  5,089  — 
Comprehensive loss $ (68,972) $ (29,899) $ (148,549) $ (101,711)
See accompanying notes to condensed consolidated financial statements (unaudited).

5
Table of Contents
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
(In thousands, except share data)
  Common Stock Additional Paid-in Capital Accumulated other comprehensive income Accumulated Deficit Total Stockholders’ Equity (Deficit)
  Shares Amount
Balance at December 31, 2020 81,351,533  $ 8  $ 656,827  $ —  $ (655,488) $ 1,347 
Issuance of common stock in connection with the March 2021 Public Offering (see Note 10) 17,142,857  2  27,707  —  —  27,709 
Restricted stock awards issued 1,772,500  —  —  —  —  — 
Shares withheld to cover taxes related to vesting of restricted stock awards (2,644) —  (7) —  —  (7)
Stock-based compensation —  —  3,464  —  —  3,464 
Net loss —  —  —  —  (46,151) (46,151)
Balance at March 31, 2021 100,264,246  $ 10  $ 687,991  $ —  $ (701,639) $ (13,638)
Issuance of common stock in connection with the March 2021 and May 2021 Public Offerings (see Note 10) 55,119,222  6  53,084  —  —  53,090 
Issuance of common stock upon cash exercise of warrants 49,000  —  49  —  49 
Issuance of common stock - ESPP 173,675  —  196  —  —  196 
Restricted stock awards issued 5,000  —  —  —  —  — 
Restricted stock awards cancelled (124,500) —  —  —  —  — 
Shares withheld to cover taxes related to vesting of restricted stock awards (350,356) —  (300) —  —  (300)
Stock-based compensation —  —  2,993  —  —  2,993 
Net loss —  —  —  —  (33,426) (33,426)
Balance at June 30, 2021 155,136,287  $ 16  $ 744,013  $ —  $ (735,065) $ 8,964 
Change in fair value of financial instruments attributed to credit risk change —  —  —  5,089  —  5,089 
Issuance of common stock upon cash exercise of warrants 110,000  —  110  —  —  110 
Restricted stock awards cancelled (17,833) —  —  —  —  — 
Shares withheld to cover taxes related to vesting of restricted stock awards (19,998) —  (20) —  —  (20)
Stock-based compensation —  —  1,091  —  —  1,091 
Net loss —  —  —  —  (74,061) (74,061)
Balance at September 30, 2021 155,208,456  $ 16  $ 745,194  $ 5,089  $ (809,126) $ (58,827)

6
Table of Contents
  Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders’ Equity
  Shares Amount
Balance at December 31, 2019 48,137,880  $ 5  $ 528,810  $ (513,179) $ 15,636 
Issuance of common stock in connection with ATM (see Note 10) 202,098  —  1,082  —  1,082 
Issuance of common stock - exercise of stock options 19,708  —  73  —  73 
Restricted stock awards issued/restricted stock units released 1,286,499  —  —  —  — 
Shares withheld to cover taxes related to vesting of restricted stock awards (4,088) —  (25) —  (25)
Stock-based compensation —  —  3,401  —  3,401 
Net loss —  —  —  (19,146) (19,146)
Balance at March 31, 2020 49,642,097  $ 5  $ 533,341  $ (532,325) $ 1,021 
Issuance of common stock in connection with the 2020 Public Offering (see Note 10) 31,700,000  3  103,263  —  103,266 
Issuance of common stock in connection with ATM 474,558  —  2,280  —  2,280 
Issuance of common stock - ESPP and exercise of stock options 69,398  —  177  —  177 
Restricted stock awards issued/restricted stock units released 60,168  —  —  —  — 
Shares withheld to cover taxes related to vesting of restricted stock awards (645,754) —  (2,777) —  (2,777)
Issuance of common stock upon cash exercise of warrants and issuance of Reload Warrants 200  —  2  —  2 
Short-swing profit disgorgement —  —  187  —  187 
Reclassification from financial instruments liability to equity —  —  11,015  —  11,015 
Stock-based compensation —  —  6,034  —  6,034 
Net loss —  —  —  (52,666) (52,666)
Balance at June 30, 2020 81,300,667  $ 8  $ 653,522  $ (584,991) $ 68,539 
Shares withheld to cover taxes related to vesting of restricted stock awards (20,381) —  (67) —  (67)
Stock-based compensation —  —  1,637  —  1,637 
Net loss —  —  —  (29,899) (29,899)
Balance at September 30, 2020 81,280,286  $ 8  $ 655,092  $ (614,890) $ 40,210 

See accompanying notes to condensed consolidated financial statements (unaudited).
7
Table of Contents
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
  Nine Months Ended September 30,
  2021 2020
Cash flows from operating activities:
Net loss $ (153,638) $ (101,711)
Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities:
Loss on issuance of financial instruments —  64,049 
Change in fair value of financial instruments 20,737  (30,971)
Stock-based compensation 7,548  11,072 
Depreciation 738  181 
         Noncash lease expenses 1,035  542 
Noncash interest expenses 2,152  992 
Changes in operating assets and liabilities:
Accounts receivable (2,964) (1,243)
Inventories (1,908) (2,912)
Prepaid and other assets 486  (9,070)
Accounts payable (3,252) (505)
Accrued expenses and other liabilities 5,996  2,900 
Accrued compensation (1,261) 1,283 
         Operating lease liabilities (1,071) (357)
Net cash, cash equivalents and restricted cash used in operating activities (125,402) (65,750)
Cash flows from investing activities:
Proceeds from sale of Softcup line of business 250  250 
Maturities of short-term investments —  8,233 
Purchases of property and equipment (2,886) (833)
Net cash, cash equivalents and restricted cash (used in) provided by investing activities (2,636) 7,650 
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants, net of discounts, fees and commissions - Public Offerings 81,534  103,738 
Proceeds from issuance of common stock - exercise of warrants 159  2 
Proceeds from issuance of common stock, net of commissions - ATM transactions —  3,781 
Proceeds from issuance of common stock - ESPP and exercise of stock options 196  337 
Borrowings under convertible notes —  25,000 
Short-swing profit disgorgement —  187 
Cash paid for financing costs (735) (867)
Payments of tax withholdings related to vesting of restricted stock awards (327) (2,869)
Net cash, cash equivalents and restricted cash provided by financing activities 80,827  129,309 
Net change in cash, cash equivalents and restricted cash (47,211) 71,209 
Cash, cash equivalents and restricted cash, beginning of period 72,251  16,625 
Cash, cash equivalents and restricted cash, end of period $ 25,040  $ 87,834 
Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities $ —  $ 7,618 
Purchases of property and equipment included in accounts payable and accrued expenses $ 714  $ 73 
Reclassification of financial instruments liability to equity $ —  $ 11,015 

See accompanying notes to condensed consolidated financial statements (unaudited).
8
Table of Contents
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1.Description of Business and Basis of Presentation

Description of Business

Evofem is a San Diego-based, commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).

The Company’s first commercial product, Phexxi, was approved by the FDA on May 22, 2020 and is the first and only FDA-approved, hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. The Company commercially launched Phexxi in September 2020.

Evofem’s pipeline product candidate, EVO100, is being evaluated for the prevention of chlamydia and gonorrhea in women - two of the most pervasive STIs in the United States. Currently, there are no FDA-approved prescription products for the prevention of either of these dangerous infections.

Basis of Presentation and Principles of Consolidation

The Company prepared the unaudited interim condensed consolidated financial statements included in this Quarterly Report in accordance with accounting principles generally accepted (GAAP) in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q.

The Company’s financial statements are presented on a consolidated basis, which include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited financial statements and should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2020 included in its Annual Report on Form 10-K as filed with the SEC on March 4, 2021 (the 2020 Audited Financial Statements).

The unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company’s audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statements of convertible preferred stock and stockholders’ deficit for the periods presented. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results expected for the full year. The condensed consolidated balance sheet as of December 31, 2020 was derived from the 2020 Audited Financial Statements.

Risks, Uncertainties and Going Concern

The Company is susceptible to risks and uncertainties associated with the COVID-19 pandemic, which is affecting its employees, customers, communities and business operations, as well as the U.S. and global economies and financial markets.

Any disruptions in the commercialization of Phexxi and/or the completion of the Company's clinical trials, data analysis or readouts and/or any disruption in its supply chain could have a material adverse effect on its business, results of operations and financial condition. The full extent to which the COVID-19 pandemic will directly or indirectly impact its business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the success of ongoing COVID-19 vaccination efforts, the emergence, prevalence and strength of variant strains, and the actions taken to contain or treat the disease, as well as the economic impact on local, regional, national and international markets. The COVID-19 pandemic has led to a slower than forecasted uptake of Phexxi due to reduced access to medical offices and HCPs, and has also affected the Company’s ability to timely screen and enroll participants in its pivotal Phase 3 clinical trial of EVO100 (EVOGUARD).

The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities, in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.

9
Table of Contents
The Company’s principal operations have been related to research and development, including the development of Phexxi, and to its commercially related sales and marketing efforts. Additional activities have included raising capital, recruiting personnel and establishing and maintaining a corporate infrastructure to support a commercial product. The Company has incurred operating losses and negative cash flows from operating activities since inception. As described in Note 5- Convertible Notes and Note 10- Stockholders' Equity (Deficit), the Company received net proceeds of approximately $81.5 million upon the sale and issuance of common stock and warrants to purchase common stock from two underwritten public offerings that occurred in the first half of 2021, gross proceeds of $50.0 million from the issuance of convertible notes in the second and fourth quarter of 2020, net proceeds of approximately $103.7 million upon the sale and issuance of common stock from an underwritten public offering in June 2020, and $3.8 million from its “at the market” (ATM) program, net of commissions, in 2020. As of September 30, 2021, the Company had cash and cash equivalents of $14.9 million, $9.0 million in restricted cash from the Adjuvant Notes (as defined in Note 5- Convertible Notes) that is available for use, a working capital deficit of $39.8 million and an accumulated deficit of $809.1 million.

The Company is subject to risks common to other life science companies in the development and early commercial stage including, but not limited to, uncertainty regarding the commercial success of Phexxi and the development of its pipeline product candidate, EVO100; potential disruption of its research and development and commercialization activities as a result of the COVID-19 pandemic; lack of marketing and sales history; potential development by its competitors of new and competitive technological innovations; dependence on key personnel; market acceptance of Phexxi or any other future approved products, if any; product liability; protection of proprietary technology; ability to raise additional financing; and compliance with the FDA and other government regulations, including post marketing regulations. Management’s plans to meet its short- and long-term operating cash flow requirements include generating recurring product revenue and obtaining additional funding, such as through the issuance of its capital stock, non-dilutive financings, or through collaborations or partnerships with other companies.

The Company's common stock is listed on the Nasdaq Capital Market (Nasdaq). On August 23, 2021, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department (the Staff) notifying the Company that, for the preceding 30 consecutive trading days, the closing bid price for the Company's common stock was below the minimum $1.00 per share requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement).

The notification has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq Listing Rules, the Company has been provided an initial period of 180 calendar days, or until February 21, 2022 (the Compliance Date), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company’s common stock is at least $1.00 for a minimum of 10 consecutive trading days, the Staff will provide the Company written confirmation of compliance with the Bid Price Requirement.

If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second 180 calendar day compliance period, by effecting a reverse stock split, if necessary.

If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance or otherwise maintain compliance with any of the other listing requirements. The Company is monitoring the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement. If the Company's common stock is delisted from Nasdaq, the consequences could include: adversely affecting the Company's ability to obtain equity financing at acceptable terms, a negative effect on the common stock trading volume, price, and an increase in the stock volatility, and a possible loss of confidence by shareholders, employees, and business partners.

While the Company has recognized limited revenues since the launch of Phexxi in September 2020, the Company anticipates it will continue to incur net losses for the foreseeable future. According to management estimates, liquidity resources as of September 30, 2021 are not sufficient to maintain the Company’s planned level of operations for the twelve months from the date of issuance of these condensed consolidated financial statements.

These circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, enter into collaborative agreements with strategic partners, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.

10
Table of Contents
If the Company is not able to obtain the required funding in the near term, through equity or debt financings or other means, or is unable to obtain funding on terms favorable to the Company, this will have a material adverse effect on its commercialization and development operations and its strategic development plan for future growth. If the Company cannot successfully raise additional funding and implement its strategic development plan, the Company may be forced to make reductions in spending, including spending in connection with its commercialization activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in the condensed consolidated financial statements, suspend or curtail planned operations or cease operations entirely. Any of these could materially and adversely affect its liquidity, financial condition and business prospects and the Company would not be able to continue as a going concern.

Subsequent Events

Subsequent events were evaluated through the filing date of this Quarterly Report, November 15, 2021. See Note 10- Stockholders' Equity (Deficit) for discussion of subsequent events which occurred in October 2021.

2.Summary of Significant Accounting Policies

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.

Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right-of-use assets and lease liabilities, the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in Note 3- Revenue, Note 5- Convertible Notes, Note 7- Fair Value of Financial Instruments, Note 8- Commitments and Contingencies, and Note 11- Stock-based Compensation. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, who is the Chief Executive Officer of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.

The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.

The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of September 30, 2021, based on the evaluation of these factors the Company did not record an allowance for doubtful
11
Table of Contents
accounts. For the three and nine months ended September 30, 2021, the Company’s three largest customers combined made up approximately 69% and 78% of its gross product sales, respectively. For the three and nine months ended September 30, 2020, the Company’s three largest customers combined made up approximately 93% of its gross product sales, respectively. As of September 30, 2021 and December 31, 2020, the Company's three largest customers combined made up 68% and 95%, respectively, of its trade accounts receivable balance.

Significant Accounting Policies

There have been no changes to the significant accounting policies that were described in Note 2- Summary of Significant Accounting Policies of the 2020 Audited Financial Statements.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of readily available cash in checking accounts and money market funds. Restricted cash consists of cash held in monthly time deposit accounts and letters of credit, which are collateral for the Company’s credit cards, facility leases and fleet leases, as described in Note 8- Commitments and Contingencies. As of September 30, 2021, the Company maintained letters of credit of $0.8 million and $0.3 million for its office lease and fleet leases, respectively. Additionally, the remaining $9.0 million of the $25.0 million received from the issuance of Adjuvant Notes in the fourth quarter of 2020, is classified as restricted cash as the Company is contractually obligated to use the funds for specific purposes.

The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the condensed consolidated statements of cash flows (in thousands): 
Nine Months Ended September 30,
2021 2020
Cash and cash equivalents $ 14,856  $ 86,697 
Restricted cash 9,384  337 
Restricted cash included in other noncurrent assets 800  800 
Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows $ 25,040  $ 87,834 
Net Loss Per Share

Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented. Potentially dilutive securities excluded from the calculation of diluted net loss per share are summarized in the table below.
Three and Nine Months Ended September 30,
2021 2020
Unvested restricted common stock subject to repurchase 934,000  70,000 
Common stock to be purchased under the 2019 ESPP 518,104  64,442 
Options to purchase common stock 10,467,527  8,972,112 
Warrants to purchase common stock 67,767,107  10,426,107 
Total 79,686,738  19,532,661 

Recently Issued Accounting Pronouncements — Not Yet Adopted

In August 2020, the Financial Accounting Standards Board issued ASU No. 2020-06, Debt (ASU No. 2020-06), removing, modifying and adding certain disclosure requirements of ASC 470, Debt with Conversion and Other Options, and ASC 815, Derivatives and Hedging—Contracts in Entity’s Own Equity. ASU No. 2020-06 will be effective for the Company beginning January 1, 2024. The Company is currently evaluating when to adopt ASU 2020-06 and the expected impact on the condensed consolidated financial statements.

12
Table of Contents
3.Revenue

The Company recognizes revenue from the sale of Phexxi in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; (5) recognize revenue when (or as) the entity satisfies a performance obligation.

In accordance with ASC 606, the Company recognizes revenue when its performance obligation is satisfied by transferring control of the product to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. Payment terms typically range from 45 to 66 days, include prompt pay discounts, and vary by customer. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable policy in Note 2- Summary of Significant Accounting Policies to the 2020 Audited Financial Statements.

The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when the performance obligation is satisfied. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue.

Phexxi is sold to customers at the wholesale acquisition cost (WAC), or in some cases at a discount to WAC. However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration reduce revenue and include the following:

•Distribution services fees
•Prompt pay and other discounts
•Product returns
•Chargebacks
•Rebates
•Patient support programs, including our co-pay programs

An estimate for variable consideration is made with each sale and is recorded in conjunction with the revenue being recognized. To calculate the variable consideration, the Company uses the expected value method. If the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed and adjustments are made if necessary. Any adjustments made to these provisions would also affect net product revenue and earnings.

In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relies on historical sales data showing the amount of various end-user consumer types, inventory reports from the wholesale distributors and mail-order specialty pharmacy, and other relevant data reports. Because Phexxi was launched in September 2020, this historical data is limited. Due to limits on historical data, the Company has also used trend analysis and professional judgment in developing these estimates.

The specific considerations that the Company uses in estimating these amounts related to variable consideration are as follows:

Distribution services fees – The Company pays distribution service fees to its wholesale distributors and mail-order specialty pharmacy. These fees are a contractually fixed percentage of WAC, and are calculated at the time of sale based on the purchase amount. The Company considers these fees to be separate from the customer’s purchase of the product, therefore, they are recorded in other current liabilities on the condensed consolidated balance sheet.

Prompt pay and other discounts – The Company incentivizes its customers to pay their invoices on time through prompt pay discounts. These discounts are an industry standard practice, and the Company offers a prompt pay discount to each wholesale distributor and retail pharmacy customer. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are typically taken by the Company’s customers, so an estimate of the discount is recorded at the
13
Table of Contents
time of sale based on the purchase amount. Prompt pay discount estimates are recorded as contra trade accounts receivable on the condensed consolidated balance sheet.

The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recognized.

Chargebacks – Certain government entities and covered entities (e.g. Veterans Administration, 340B covered entities) are able to purchase the product at a price discounted below WAC. The difference between the government or covered entity purchase price and the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount of each chargeback channel based on the expected number of claims in each channel and related chargeback that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the consolidated balance sheet.

Rebates – The Company is subject to mandatory discount obligations under the Medicaid and Tricare programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates for Medicaid and Tricare are typically invoiced in arrears. The Company estimates the amount in rebates based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as other current liabilities on the consolidated balance sheet.

Patient support programs – One type of patient support program the Company offers is a co-pay program to commercially insured patients whose insurance requires a co-pay to be made when filling their prescription. This is a voluntary program that is intended to provide financial assistance to patients meeting certain eligibility requirements. The Company estimates the amount of financial assistance for these programs based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Patient support programs estimates are recorded as other current liabilities on the consolidated balance sheet.

Product returns – Customers have the right to return product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than six months. Phexxi was commercially launched in September 2020 and there have been minimal returns as of September 30, 2021. The Company uses historical sales and return data to estimate future product returns. Product return estimates are recorded as other current liabilities on the consolidated balance sheet.

As of September 30, 2021, the total balance associated with variable considerations discussed above was approximately $2.5 million and is recorded in the condensed consolidated balance sheet in either trade accounts receivable, net, or other current liabilities.

4.Inventories

The inventory costs include all purchased materials, direct labor and manufacturing overhead. Prior to April 2020, costs incurred for the manufacture of Phexxi were recorded as research and development expenses.

Inventories consist of the following (in thousands) for the period indicated: 
September 30, 2021 December 31, 2020
Raw materials $ 498  $ 332 
Work in process(1)
2,095  4,162 
Finished goods 7,354  2,668 
Total $ 9,947  $ 7,162 
_____________________
(1) The work in process balance represents all production costs incurred for partially completed goods.

5.Convertible Notes

Baker Bros. Notes

On April 23, 2020, the Company entered into a Securities Purchase and Security Agreement (the Baker Bros. Purchase Agreement) with certain affiliates of Baker Bros. Advisors LP, as purchasers (the Baker Purchasers), and Baker Bros. Advisors LP, as designated agent, pursuant to which the Company agreed to issue and sell to the Baker Purchasers (i) convertible senior
14
secured promissory notes (the Baker Notes) in an aggregate principal amount of up to $25.0 million and (ii) warrants to purchase shares of common stock (the Baker Warrants) in a private placement.

At the initial closing date of April 24, 2020 (the Baker Initial Closing), the Company issued and sold Baker Notes with an aggregate principal amount of $15.0 million (the Baker First Closing Notes) and Baker Warrants exercisable for 3,073,770 shares of common stock.

Following the Baker Initial Closing, the Baker Purchasers had an option to purchase from the Company up to $10.0 million of Baker Notes (the Baker Purchase Rights) at the Baker Purchasers’ discretion at any time prior to the Company receiving at least $100.0 million in aggregate gross proceeds from one or more sales of equity securities.

On June 5, 2020 (the Exercise Date), the Baker Purchasers exercised the Baker Purchase Rights. At the second closing date of June 9, 2020 (the Baker Second Closing), the Baker Purchasers acquired the remaining Baker Notes with an aggregate principal amount of $10.0 million and Baker Warrants exercisable for 2,049,180 shares of common stock. With the completion of the underwritten public offering in June 2020 as further discussed in Note 10- Stockholders' Equity (Deficit), the conversion price of the Baker Notes and the exercise price of the Baker Warrants is $2.44. The Baker Warrants have a five-year term with a cashless exercise provision and are immediately exercisable at any time from their respective issuance date.

The Baker Notes have a five-year term, with no pre-payment ability. Interest on the unpaid principal balance of the Baker Notes (the Baker Outstanding Balance) accrues at 10.0% per annum with interest accrued during the first year from the two respective closing dates recognized as payment-in-kind. Accrued interest beyond the first year of the respective closing dates are to be paid in arrears on a quarterly basis in cash or recognized as payment-in-kind, at the direction of the Purchasers.
Interest expense for the three and nine months ended September 30, 2021 was approximately $0.7 million and $2.1 million, respectively. The Baker Purchasers elected to have the accrued interest for first quarter of 2021 paid-in-kind, and the accrued interest for the second and third quarters of 2021 paid in cash.

The Baker Notes are convertible at any time at the option of the Baker Purchasers at the conversion price of $2.44 per share. The Baker Notes are callable by the Company on 10 days’ written notice beginning on the third anniversary of the Baker Initial Closing. The call price will equal 100% of the Baker Outstanding Balance plus accrued and unpaid interest if the Company’s common stock as measured using a 30-day volume weighted average price (VWAP) is greater than the benchmark price of $4.99 as stated in the Baker Bros. Purchase Agreement, or 110% of the Baker Outstanding Balance plus accrued and unpaid interest if the VWAP is less than such benchmark price. The Baker Purchasers also have the option to require the Company to repurchase all or any portion of the Baker Notes in cash upon the occurrence of certain events. In a repurchase event, as defined in the Baker Bros. Purchase Agreement, the repurchase price will equal 110% of the Baker Outstanding Balance plus accrued and unpaid interest. In an event of default or the Company’s change of control, the repurchase price will equal to the sum of (x) three times of the Baker Outstanding Balance plus (y) the aggregate value of future interest that would have accrued. Collectively, these options are the “Embedded Features” of the Baker Notes.

The Company's stockholders approved the issuance of the shares issuable upon conversion of the Baker Notes and the exercise of the Baker Warrants in order to comply with Nasdaq Listing Rules 5635(b) and 5635(d) at its special meeting of stockholders held on June 18, 2020 (the Approval Date).

The Company evaluated whether any of the Embedded Features required bifurcation as a separate component of equity. The Company elected the fair value option (FVO) under ASC 825, Financial Instruments (ASC 825), as the Baker Notes are qualified financial instruments and are, in whole, classified as liabilities. Under the FVO, the Company recognized the hybrid debt instrument at fair value inclusive of the Embedded Features. The Company also determined that the Baker Warrants and the Baker Purchase Rights were free standing financial instruments and were classified as liabilities at the time of issuance in accordance with ASC 480, Distinguishing Liabilities From Equity due to the required stockholders’ approval noted above.

Under the valuation methods as described in Note 7- Fair Value Financial Instruments, the Company recorded the following in the condensed consolidated financial statements related to the Baker Notes and Baker Warrants during the quarter ended June 30, 2020: (i) an aggregate of $58.1 million in convertible notes and an aggregate of $46.7 million for warrants and purchase rights liability at the Baker Initial Closing and Exercise Date; (ii) a $64.0 million loss on issuance of financial instruments recognized at the Baker Initial Closing in the condensed consolidated statement of operations; (iii) an aggregate $34.1 million gain on fair value changes of financial instruments as a result of mark-to-market adjustments on the Baker Notes, Baker Warrants and Baker Purchase Rights recognized respectively at the Exercise Date, Approval Date and the quarter ended June 30, 2020, in the condensed consolidated statement of operations; (iv) a $15.8 million reclassification from purchase rights liability to the convertible notes and warrants liability on the Exercise Date; and (v) an $11.0 million reclassification from warrants liability to additional paid-in capital in the condensed consolidated balance sheet on the Approval Date. In the third quarter of 2021, the Company concluded that there was a change in the underlying instrument-specific credit risk between the
15
issuance dates for the Baker Notes and September 30, 2021. As a result of this difference in credit risk, the Company recognized a $5.1 million gain in the fair value of the convertible notes that is presented separately as a component of other comprehensive income. The change in fair value attributed to the change in the underlying instrument-specific credit risk was determined by taking the difference between the fair value of the Baker Notes with and without the credit risk change.

Using the same valuation methods discussed in Note 7- Fair Value Financial Instruments, the Company recorded a $29.5 million loss in fair value of financial instruments as a result of mark-to-market adjustments recognized on the Baker Notes for the quarter ended September 30, 2021 in the condensed consolidated financial statements. The mark-to-market adjustment was in consideration of the increased probability of the failure to meet the affirmative covenant to achieve $100.0 million in cumulative net sales of Phexxi by June 30, 2022, and thus paying a higher repurchase price.
The Baker Notes contain various customary affirmative and negative covenants agreed to by the Company. The Company was in compliance with all applicable covenants at September 30, 2021. The Baker Notes also include customary events of default as set forth in the Baker Bros. Purchase Agreement, such that, in an event of default, the Baker Purchasers will have the right to accelerate repayment of the aggregate loan balance then outstanding.

As of September 30, 2021, the Baker Notes are recorded in the condensed consolidated balance sheet as short-term convertible notes payable with a total balance of $68.7 million.

Adjuvant Notes

On October 14, 2020, the Company entered into a Securities Purchase Agreement (the Adjuvant Purchase Agreement) with Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, the Adjuvant Purchasers), pursuant to which the Company sold unsecured convertible promissory notes (the Adjuvant Notes) in aggregate principal amount of $25.0 million.

The Adjuvant Notes have a five-year term with interest accruing at 7.5% per annum on a quarterly basis in arrears to the outstanding balance of the Adjuvant Notes and are recognized as payment-in-kind. Interest expense pertaining to the Adjuvant Notes for the three and nine months ended September 30, 2021 was approximately $0.5 million and $1.5 million, respectively, and is included in long-term convertible notes payable on the accompanying consolidated balance sheet as of September 30, 2021. In connection with certain Company change of control transactions, the Adjuvant Notes may be prepaid at the option of the Company or will become payable at the option of the Adjuvant Purchasers.

The Adjuvant Notes are convertible, subject to customary 4.99% and 19.99% beneficial ownership limitations, into shares of the Company’s common stock, par value $0.0001 per share, at any time at the option of the Adjuvant Purchasers at a conversion price of $3.65 per share. To the extent not previously prepaid or converted, the Adjuvant Notes will automatically convert into shares of the Company’s common stock at a conversion price of $3.65 per share immediately following the earliest of the time at which the (i) 30-day value-weighted average price of the Company’s common stock is $10.00 per share, or (ii) Company achieves cumulative net sales from the sales of Phexxi of $100,000,000, provided such net sales are achieved prior to July 1, 2022.

The Adjuvant Notes contain various customary affirmative and negative covenants agreed to by the Company. The Company was in compliance with all applicable covenants at September 30, 2021. The Adjuvant Notes also include customary events of default as set forth in the Adjuvant Purchase Agreement, such that, in an event of default, the Adjuvant Purchasers will have the right to accelerate repayment of the aggregate loan balance then outstanding.

The Adjuvant Notes are accounted for in accordance with authoritative guidance for convertible debt instruments. The $25.0 million in proceeds is considered to be restricted cash for financial reporting purposes due to contractual stipulations that specify the types of expenses the money can be spent on and how it must be allocated. As of September 30, 2021, there is $9.0 million in proceeds remaining that is included in restricted cash on the accompanying consolidated balance sheet.

As of September 30, 2021, the Adjuvant Notes are recorded in the condensed consolidated balance sheet as long-term convertible notes payable with a total balance of $26.7 million. The balance is comprised of $24.8 million in principal, net of unamortized debt issuance costs, and $1.9 million in accrued interest.

16
6.Balance Sheet Details

Prepaid and Other Current Assets
Prepaid and other current assets consist of the following (in thousands): 
September 30, 2021 December 31, 2020
Selling and marketing related costs $ 13,262  $ 15,414 
Insurance 1,775  900 
Clinical trial related costs 377  304 
Subscriptions for IT platforms 147  — 
Manufacturing related costs 144  382 
Flex note receivable (1)
—  250 
Other 980  800 
Total $ 16,685  $ 18,050 
_______________________
(1) In July 2016, the Company entered into an Asset Purchase Agreement with The Flex Company (Flex), whereby Flex would acquire certain assets and assume certain liabilities associated with the Company’s Softcup line of business (Softcup). Total consideration for the Softcup sale was $1.9 million, with $0.6 million received in cash at closing and the remaining $1.3 million due and payable under a note in favor of the Company (the Flex Note) through January 1, 2021 (the Maturity Date). The Flex Note bears simple interest at a rate of 5.0% per annum on the remaining principal amount outstanding. An annual principal payment of approximately $0.3 million and the annual accrued and unpaid interest are payable each January 1, beginning in 2017 through the Flex Maturity Date. The note was paid off on January 4, 2021.

The Flex Note is secured by the Softcup assets and has been recorded at fair value. The Company’s incremental borrowing rate and the stated interest rate of the Flex Note are materially consistent.

Property and Equipment, Net

Property and equipment, net, consists of the following (in thousands):
Useful Life September 30, 2021 December 31, 2020
Research and production equipment 5 years $ 623  $ 623 
Computer equipment and software 3 years 508  444 
Office furniture 5 years 881  629 
Leasehold improvements
5 years or less
3,489  1,540 
Construction in-process —  2,157  2,249 
7,658  5,485 
Less: accumulated depreciation (1,889) (1,151)
Total, net $ 5,769  $ 4,334 

Depreciation expense was approximately $0.2 million and $0.1 million for the three months ended September 30, 2021 and 2020, respectively. Depreciation expense was approximately $0.7 million and $0.2 million for the nine months ended September 30, 2021 and 2020, respectively.

Other Noncurrent Assets

Other noncurrent assets consist of the following (in thousands):
September 30, 2021 December 31, 2020
Restricted cash included in noncurrent assets $ 800  $ 800 
Prepaid directors & officers' insurance 136  214 
Other 55  34 
Total $ 991  $ 1,048 

17
Accrued Expenses

Accrued expenses consist of the following (in thousands):
September 30, 2021 December 31, 2020
Clinical trial related costs $ 5,577  $ 1,417 
Selling and marketing related costs 2,320  564 
Legal and other professional fees 301  1,631 
Manufacturing related costs 210  498 
Other 614  366 
Total $ 9,022  $ 4,476 

7.Fair Value of Financial Instruments

The fair values of the Company’s assets, including the money market funds, investments in marketable fixed income debt securities classified as cash and cash equivalents, restricted cash, Flex Note receivable, and the Baker Notes, measured on a recurring basis are summarized in the following tables, as applicable (in thousands):
  September 30, 2021 Quoted Prices in Active Markets for Identical Assets
(Level 1) 		Significant Other Observable Inputs
(Level 2) 		Significant Unobservable Inputs
(Level 3)
Money market funds (1)
$ 22,746  $ 22,746  $ —  $ — 
Total assets $ 22,746  $ 22,746  $ —  $ — 
Convertible notes payable (2)
$ 68,724  $ —  $ —  $ 68,724 
Total liabilities $ 68,724  $ —  $ —  $ 68,724 

  December 31, 2020 Quoted Prices in Active Markets for Identical Assets
(Level 1) 		Significant Other Observable Inputs
(Level 2) 		Significant Unobservable Inputs
(Level 3)
Money market funds (1)
$ 53,485  $ 53,485  $ —  $ — 
Fixed income debt securities classified as cash and cash equivalents 16,498  —  16,498  — 
Flex note receivable 250  —  250  — 
Total assets $ 70,233  $ 53,485  $ 16,748  $ — 
Convertible notes payable (2)
$ 50,752  $ —  $ —  $ 50,752 
Total liabilities $ 50,752  $ —  $ —  $ 50,752 
_____________________
(1) Included as a component of cash and cash equivalents and restricted cash on the accompanying condensed consolidated balance sheet.
(2) The convertible notes payable as of December 31, 2020 on the accompanying condensed consolidated balance sheet also includes approximately $1.7 million in accrued interest on the Baker Notes.

The Baker Warrants and the Baker Purchase Rights, as discussed in Note 5- Convertible Notes, were determined to be classified as liabilities. Therefore, they were stated at fair value at issuance and subject to mark-to-market at each reporting date until a subsequent event occurs that would change their classification. They were considered Level 3 instruments because the fair value measurement was based, in part, on significant inputs not observed in the market.
18

The following tables summarize the changes in Level 3 financial liabilities measured at fair value on a recurring basis for the three and nine months ended September 30, 2021.
  Baker First Closing Notes Baker Second Closing Notes Total
Balance at June 30, 2021 $ 26,585  $ 17,723  $ 44,308 
Change in fair value presented in the Statements of Operations
17,703  11,802  29,505 
Change in fair value presented in the Statements of Comprehensive Operations
(3,053) (2,036) (5,089)
Balance at September 30, 2021 $ 41,235  $ 27,489  $ 68,724 

  Baker First Closing Notes Baker Second Closing Notes Total
Balance at December 31, 2020 $ 30,451  $ 20,301  $ 50,752 
Change in fair value presented in the Statements of Operations (1)
13,837  9,224  23,061 
Change in fair value presented in the Statements of Comprehensive Operations
(3,053) (2,036) (5,089)
Balance at September 30, 2021 $ 41,235  $ 27,489  $ 68,724 
_____________________
(1) The total change in fair value on the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2021 includes approximately $2.3 million in accrued interest settled in kind.

The following tables summarize the changes in Level 3 financial liabilities measured at fair value on a recurring basis for the three and nine months ended September 30, 2020.

  Baker First Closing Notes Baker Second Closing Notes Total
Balance at June 30, 2020 $ 26,375  $ 17,583  $ 43,958 
 Change in fair value 1,863  1,242  3,105 
Balance at September 30, 2020 $ 28,238  $ 18,825  $ 47,063 


  Baker First Closing Notes Baker Second Closing Notes Baker First Closing Warrants Baker Purchase Rights Baker Second Closing Warrants Total
Balance at December 31, 2019 $ —  $ —  $ —  $ —  $ —  $ — 
 Initial liability at issuance 37,405  20,715  14,007  27,636  5,098  104,861 
 Change in fair value (9,167) (1,890) (7,408) (11,823) (682) (30,970)
 Reclassification from liability to equity (6,599) —  (4,416) (11,015)
 Exercise of Baker Purchase Rights for convertible notes —  (10,715) —  (10,715)
 Exercise of Baker Purchase Rights for warrants —  (5,098) —  (5,098)
Balance at September 30, 2020
$ 28,238  $ 18,825  $ —  $ —  $ —  $ 47,063 

Baker Notes

The fair value of the Baker Notes issued as described in Note 5- Convertible Notes, and subsequent changes in fair value recorded at each reporting date, were determined using a Monte Carlo simulation-based model. Monte Carlo simulation was used to take into account several factors including the future value of the Company's common stock, a potential change of control event, the probability of meeting certain debt covenants, the maturity term of the Baker Notes, the probability of an event of voluntary conversion of the Baker Notes, exercise of the put right, and exercise of the Company's call right.

19
Baker Warrants

The fair value of the Baker Warrants issued during the second quarter of 2020 as described in Note 5- Convertible Notes, and the respective changes in fair value of these warrants as a result of mark-to-market, were determined using the Black-Scholes option pricing model based on the following weighted-average assumptions for the period indicated.

Nine Months Ended September 30, 2020
Expected volatility 93.7  %
Risk-free interest rate 0.4  %
Expected dividend yield —  %
Expected term (years) 4.9

Baker Purchase Rights

The fair value of the Baker Purchase Rights, and the subsequent change in fair value of these rights upon exercise of such rights, was determined as the maximum of (i) the fair value of rights to purchase the additional $10 million Baker Notes and (ii) the fair value of the shares of on as-if converted basis, which was determined by the lattice model. The fair value of rights to purchase an additional 2,049,180 Baker Warrants was valued using a Geske option-pricing model. The Geske model was based on the applicable assumptions, including the underlying stock price, warrant exercise price, the exercise price of the rights to purchase the Baker Warrants, the term of the Baker Warrants, the term of the rights to purchase the Baker Warrants, the expected volatility of the Company’s peer group, risk-free interest rate and expected dividend.

8.Commitments and Contingencies

Operating Leases

Fleet Leases

In December 2019, the Company and Enterprise FM Trust (the Lessor) entered into a Master Equity Lease Agreement whereby the Company leases vehicles to be delivered by the Lessor from time to time with various monthly costs depending on the vehicles delivered for a term of 24 or 36 months, commencing on each corresponding delivery date. The leased vehicles are for use by eligible employees of the Company's commercial operations personnel. There was a total of 72 leased vehicles as of September 30, 2021. The Company maintains a letter of credit as collateral in favor of the Lessor, which was included in restricted cash in the condensed consolidated balance sheet. As of September 30, 2021 and December 31, 2020, this letter of credit was $0.3 million. The Company determined that the leased vehicles are accounted for as operating leases under ASC 842, Leases.

2020 Lease and the First Amendment

On October 3, 2019, the Company entered into an office lease for approximately 24,474 square feet (the Existing Premises) pursuant to a non-cancelable lease agreement (the 2020 Lease). The 2020 Lease commenced on April 1, 2020 and will expire on September 30, 2025, unless terminated earlier in accordance with its terms. The Company has a right to extend the term of the lease for an additional five years and does not anticipate exercising such extension. The Company provided the landlord with a $750,000 security deposit in the form of a letter of credit for the Existing Premises. On April 14, 2020, the Company entered into the first amendment to the 2020 Lease for an additional 8,816 rentable square feet of the same office location (the Expansion Premises), which commenced on September 1, 2020 and will expire on September 30, 2025. The Company provided an additional $50,000 in a letter of credit for the Expansion Premises. As of September 30, 2021 and December 31, 2020, restricted cash maintained as collateral for the Company’s security deposit was $0.8 million.

2015 Lease

Effective January 30, 2015, the Company entered into a sublease for office space under a noncancelable lease agreement that expired in March 2020 (the 2015 Lease), which is the Company’s primary office space. The 2015 Lease expired on March 31, 2020.
20
Supplemental Financial Statement Information
Three Months Ended September 30, Nine Months Ended September 30,
Lease Cost (in thousands) Classification 2021 2020 2021 2020
Operating lease expense Research and development $ 115  $ 118  $ 387  $ 273 
Operating lease expense Selling and marketing 256  167  753  298 
Operating lease expense General and administrative 212  181  620  427 
Total $ 583  $ 466  $ 1,760  $ 998 

Lease Term and Discount Rate September 30, 2021 December 31, 2020
Weighted Average Remaining Lease Term (in years) 3.79 4.43
Weighted Average Discount Rate 12  % 12  %

Maturity of Operating Lease Liabilities (in thousands) September 30, 2021
Remainder of 2021 $ 649 
Year ending December 31, 2022 2,480 
Year ending December 31, 2023 2,163 
Year ending December 31, 2024 2,192 
Year ending December 31, 2025 1,502 
Total lease payments 8,986 
Less: imputed interest (1,794)
Total $ 7,192 

Nine Months Ended September 30,
Other information (in thousands) 2021 2020
Cash paid for amounts included in the measurement of lease liabilities:
     Operating cash outflows in operating leases $ 1,779  $ 552 

Other Contractual Commitments
In November 2019, the Company entered into a supply and manufacturing agreement with a third-party to manufacture Phexxi and potentially other product candidates in accordance with all applicable current good manufacturing practice regulations, pursuant to which the Company has certain minimum purchase commitments based on the forecasted product sales.

Contingencies

From time to time the Company may be involved in various lawsuits, legal proceedings or claims that arise in the ordinary course of business. There were no claims or actions pending against the Company as of September 30, 2021 and December 31, 2020, which management believes would have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, results of operations or cash flows. However, litigation is subject to inherent uncertainties and an adverse result in any matter that may arise from time to time could harm the Company’s business.

Intellectual Property Rights

In 2014, the Company entered into an amended and restated license agreement (the Rush License Agreement) with Rush University Medical Center (Rush University) pursuant to which Rush University granted the Company an exclusive, worldwide license of certain patents and know-how related to its multipurpose vaginal pH modulator technology. Pursuant to the Rush License Agreement, the Company is obligated to pay to Rush University an earned royalty based upon a percentage of net sales in the range of mid-single digits. In September 2020, the Company entered the first amendment to the Rush License Agreement, pursuant to which the Company is also obligated to pay a minimum annual royalty amount of $100,000 to the
21
extent the earned royalties do not equal or exceed $100,000 commencing January 1, 2021. Such royalty costs were $0.1 million and $0.2 million for the three and nine months ended September 30, 2021, respectively.

9.Related-party Transactions

Consulting Agreements

Effective April 1, 2019, the Company entered into a two-year consulting agreement with Thomas Lynch (the 2019 Consulting Agreement). The 2019 Consulting Agreement provided for (i) annual compensation of $0.4 million, including $0.1 million related to Mr. Lynch’s board services, (ii) an annual grant of 150,000 restricted stock units (RSUs), which vested quarterly over one year from the grant date and (iii) an annual bonus of up to 100% of Mr. Lynch’s annual consulting fees based upon the achievement of the Company’s corporate goals and objectives as determined by and subject to approval of the board of directors. The 2019 Consulting Agreement terminated on April 1, 2020 upon the passing of Mr. Lynch.

Consulting fees incurred under the 2019 Consulting Agreement were zero for both the three months ended September 30, 2021 and 2020, respectively, and zero and $0.1 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021 and December 31, 2020, excluding board fees, there was no accrued compensation owed to Mr. Lynch.

10.Stockholders' Equity (Deficit)

Warrants

In April and June 2020, pursuant to the Baker Bros. Purchase Agreement as discussed in Note 5- Convertible Notes, the Company issued warrants to purchase up to 5,122,950 shares of common stock in a private placement at an exercise price of $2.44 per share. In May 2021, pursuant to the May 2021 Public Offering as defined below, the Company issued warrants to purchase up to 57,500,000 shares of common stock at an exercise price of $1.00 per share, of which warrants to purchase 49,000 and 110,000 shares of common stock were exercised in June and July 2021, respectively.

As of September 30, 2021, warrants to purchase up to 67,767,107 shares of the Company’s common stock remain outstanding at a weighted average exercise price of $1.54 per share. These warrants are summarized below:

Type of Warrants Underlying Common Stock to be Purchased Exercise Price Issue Date Exercise Period
Common Warrants 878  $ 51.24  March 30, 2012 March 30, 2012 to March 30, 2022
Common Warrants 1,171  $ 51.24  August 17, 2012 August 17, 2012 to July 17, 2022
Common Warrants 7,806  $ 3.69  June 11, 2014 June 11, 2014 to June 11, 2024
Common Warrants 848,674  $ 7.50  May 24, 2018 May 24, 2018 to May 24 2025
Common Warrants 182  $ 7.50  June 26, 2018 June 26, 2018 to June 26, 2025
Common Warrants 1,666,667  $ 6.38  April 11, 2019 October 11, 2019 to April 11, 2026
Common Warrants 2,777,779  $ 6.38  June 10, 2019 December 10, 2019 to June 10, 2026
Common Warrants 3,073,770  $ 2.44  April 24, 2020 April 24, 2020 to April 24, 2025
Common Warrants 2,049,180  $ 2.44  June 9, 2020 June 9, 2020 to June 9, 2025
Common Warrants 57,341,000  $ 1.00  May 20, 2021 May 20, 2021 to May 22, 2023
Total 67,767,107 

22
Convertible Preferred Stock

On October 12, 2021, the Company completed the initial closing of a registered direct offering with Keystone Capital Partners (Keystone Capital) (the Initial October 2021 Registered Direct Offering), whereby the Company issued 5,000 shares of Series B-1 Convertible Preferred Stock, par value $0.0001 per share, at a price of $1,000.00 per share. The Company received proceeds from the Initial October 2021 Registered Direct Offering of approximately $4.7 million, net of offering expenses. The Series B-1 Convertible Preferred Stock can be converted into shares of common stock at any time at a conversion price per share of the greater of $0.60, or the price computed as the product of 0.85 multiplied by the arithmetic average of the closing sale prices of a share of the Company's common stock during the five consecutive trading-day period immediately preceding the conversion date. On October 12, 2021, Keystone Capital converted their 5,000 shares of B-1 Convertible Preferred Stock at a conversion price of $0.63 per share into 7,936,508 shares of the Company's common stock. The common stock issued upon the conversion of the Series B-1 Convertible Preferred Stock issued in the Initial October 2021 Registered Direct Offering was registered pursuant to a shelf registration statement on Form S-3 filed with the SEC on July 30, 2021 and declared effective on August 5, 2021.

On October 26, 2021, the Company completed the additional closing of the October 2021 Registered Direct Offering (the Additional October 2021 Registered Direct Offering), whereby the Company issued 5,000 shares of Series B-2 Convertible Preferred Stock, par value $0.0001 per share, at a price of $1,000.00 per share. The Company received proceeds from the Additional October 2021 Registered Direct Offering of approximately $5.0 million, net of offering expenses. The Series B-2 Convertible Preferred Stock can be converted into shares of common stock at any time at a conversion price per share of the greater of $0.60, or the price computed as the product of 0.85 multiplied by the arithmetic average of the closing sale prices of a share of the Company's common stock during the five consecutive trading-day period immediately preceding the conversion date. The common stock issuable upon the conversion of the Series B-2 Convertible Preferred Stock issued in the Additional October 2021 Registered Direct Offering was registered pursuant to a shelf registration statement on Form S-3 filed with the SEC on July 30, 2021 and declared effective on August 5, 2021.

Common Stock

Effective January 17, 2018, the Company amended and restated its certificate of incorporation, under which the Company is currently authorized to issue up to 300,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share.

Public Offerings

On June 5, 2020, the Company completed an underwritten public offering (the 2020 Public Offering), whereby the Company issued 28,500,000 shares of common stock at a price to the public of $3.50 per share (the 2020 Public Offering Price). The Company received proceeds from the 2020 Public Offering of $93.2 million, net of underwriting discounts. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 4,275,000 shares of its common stock at the 2020 Public Offering Price, less applicable underwriting discounts. On June 10, 2020, the Company issued an additional 3,200,000 shares of common stock upon exercise of the underwriters’ option and received $10.5 million in proceeds from this exercise, net of underwriting discounts. The common stock issued in the 2020 Public Offering were registered pursuant to a shelf registration statement on Form S-3 filed with the SEC on November 18, 2019 and declared effective on December 2, 2019.

On March 29, 2021, the Company completed an underwritten public offering (the March 2021 Public Offering), whereby the Company issued 17,142,857 shares of common stock at a price to the public of $1.75 per share (the March 2021 Public Offering Price). The Company received proceeds from the March 2021 Public Offering of approximately $28.0 million, net of underwriting discounts. In addition, the Company granted the underwriters a 30-day overallotment option to purchase up to an additional 2,571,428 shares of its common stock at the March 2021 Public Offering Price, less applicable underwriting discounts. On April 6, 2021, the underwriters exercised their overallotment option in full and the Company received proceeds of approximately $4.2 million, net of underwriting discounts. The common stock issued in the March 2021 Public Offering were registered pursuant to a shelf registration statement on Form S-3 filed with the SEC on March 4, 2021 and declared effective on March 11, 2021.

On May 20, 2021, the Company completed an underwritten public offering (the May 2021 Public Offering), whereby the Company issued 50,000,000 shares of common stock at a price to the public of $1.00 per share and accompanying common warrants to purchase 50,000,000 shares of common stock. The common warrants have an exercise price of $1.00 per share and can be exercised any time through May 22, 2023. The Company received proceeds from the May 2021 Public Offering of approximately $46.8 million, net of underwriting discounts and fees. In addition, the Company granted the underwriters a 30-day overallotment option to purchase up to an additional 7,500,000 shares of its common stock at $0.99 per share, less applicable underwriting discounts, and/or common warrants to purchase 7,500,000 shares of common stock, at $0.01 per warrant, less applicable underwriting discounts. On May 20, 2021, the underwriters exercised their overallotment option to
23
purchase warrants in full and the Company received proceeds of approximately $0.1 million, net of underwriting discounts. On May 21, 2021, the underwriters exercised their overallotment option to purchase common stock and the Company issued an additional 2,547,794 shares of common stock and received proceeds of approximately $2.4 million, net of underwriting discounts. The common stock issued in the May 2021 Public Offering were registered pursuant to a shelf registration statement on Form S-3 filed with the SEC on March 4, 2021 and declared effective on March 11, 2021.

ATM Program

In November 2019, the Company entered into an Equity Distribution Agreement (the Equity Distribution Agreement) with Piper Sandler & Co. (Piper Sandler), which provided the Company the ability to offer and sell, from time to time, shares of its common stock in ATM offerings (as defined in Rule 415 of the Securities Act of 1933, as amended) having an aggregate offering price up to $50 million through Piper Sandler acting as sales agent. On June 2, 2020, in connection with the aforementioned 2020 Public Offering, the Equity Distribution Agreement was terminated. During the nine months ended September 30, 2020, the Company received proceeds of approximately $3.8 million in cash and cash equivalents (including $0.3 million that was included in other receivables in the condensed consolidated balance sheet at December 31, 2019), net of commissions, from the sale of 676,656 shares of its common stock.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance is as follows in common equivalent shares as of September 30, 2021: 
Common stock issuable upon the exercise of stock options outstanding 10,467,527 
Common stock issuable upon the exercise of common stock warrants 67,767,107 
Common stock available for future issuance under the 2019 ESPP 2,120,046 
Common stock available for future issuance under the Amended and Restated 2014 Plan 1,960,000 
Common stock available for future issuance under the Amended Inducement Plan 755,215 
Total common stock reserved for future issuance 83,069,895 


11.Stock-based Compensation

Equity Incentive Plans
The following table summarizes stock-based compensation expense related to stock options, restricted stock awards (RSAs) and RSUs granted to employees, non-employee directors and consultants, and the 2019 ESPP (as defined below) included in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended September 30, Nine Months Ended September 30,
2021 2020 2021 2020
Research and development $ 160  $ 291  $ 1,122  $ 1,689 
Selling and marketing 272  347  1,621  2,006 
General and administrative 659  999  4,805  7,377 
Total $ 1,091  $ 1,637  $ 7,548  $ 11,072 

The 2012 Equity Incentive Plan (the 2012 Plan) provides for the issuance of RSAs, RSUs, or non-qualified and incentive common stock options to its employees, non-employee directors and consultants, from its authorized shares. In general, the options expire ten years from the date of grant and generally vest either (i) over a four-year period, with 25% exercisable at the end of one year from the employee’s hire date and the balance vesting ratably thereafter or (ii) over a three-year period, with 25% exercisable at the grant date and the balance vesting ratably thereafter. No further awards may be issued under the 2012 Plan.

On September 15, 2014, the Company's board of directors adopted, and stockholders approved, the 2014 Equity Incentive Plan (the 2014 Plan), which was amended and restated on each of May 2018 and February 26, 2019 (the Amended and Restated 2014 Plan), which among other things, increased the number of authorized shares under the 2014 Plan from 749,305 to an aggregate of 7,800,000 shares. On February 25, 2020, the Company’s board of directors approved, subject to stockholder approval, and recommended its stockholders approve at the 2020 Annual Meeting, an additional 2,000,000 authorized shares reserved for issuance under the Amended and Restated 2014 Plan to an aggregate of 11,725,515 shares, including the Evergreen Shares discussed below. Such stockholder approval was obtained on May 12, 2020. Per the terms of the Amended and Restated 2014 Plan, the shares reserved will automatically increase on each January 1 through 2024, by an amount equal to the smaller of (i) 4% of the number of shares of common stock issued and outstanding on the immediately
24
preceding December 31; or (ii) an amount determined by our board of directors. This provision resulted in an additional 3,254,061 shares (Evergreen Shares) added to the total number of authorized shares on January 1, 2021.

On July 24, 2018, upon the recommendation by the Compensation Committee, the Company's board of directors adopted the Evofem Biosciences, Inc. 2018 Inducement Equity Incentive Plan (the Inducement Plan), pursuant to which the Company reserved 250,000 shares for the issuance of equity awards under the Inducement Plan. The Inducement Plan was amended effective February 25, 2020 (the Amended Inducement Plan), which increased the number of authorized shares to an aggregate of 1,250,000 shares. The only persons eligible to receive awards under the Inducement Plan are individuals who satisfy the standards for inducement grant recipients under Nasdaq Marketplace Rule 5635(c)(4), generally, a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company. 

Stock Options

There were 70,000 and 631,200 shares of stock options granted during the three months ended September 30, 2021 and 2020, respectively, and 3,126,525 and 2,873,685 shares of stock options granted during the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, unrecognized stock-based compensation expense for employee stock options was approximately $9.3 million, which the Company expects to recognize over a weighted-average remaining period of 2.4 years, assuming all unvested options become fully vested.
Summary of Assumptions
The fair value of noncash stock-based compensation for stock options granted to employees and non-employees was estimated on the date of grant using the Black-Scholes option pricing model based on the following weighted-average assumptions for options granted for the periods indicated.
Three Months Ended September 30, Nine Months Ended September 30,
2021 2020 2021 2020
Expected volatility 102.1  % 90.7  % 101.1  % 82.4  %
Risk-free interest rate 1.0  % 0.4  % 0.7  % 0.6  %
Expected dividend yield —  % —  % —  % —  %
Expected term (years) 6.0 6.1 5.9 6.0
Expected volatility. The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry.
Risk-free interest rate. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock option grants.
Expected dividend yield. The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends.
Expected term. The expected term represents the period options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected term assumption using the practical expedient as provided for under ASC 718, Compensation-Stock Compensation, which is the midpoint between the requisite service period and the contractual term of the option.

Restricted Stock Awards and Units

There were 1,777,500 and 1,265,000 shares of RSAs granted under the Amended and Restated 2014 Plan during the nine months ended September 30, 2021, and 2020, respectively, to the Company's executive management team, certain non-executive employees and consultants. None were granted during both the three months ended September 30, 2021 and 2020. The vesting conditions for 1,767,500 shares of RSAs granted during the first quarter of 2021 and all of the RSAs granted during the first quarter of 2020 are connected to the Company’s achievement of certain performance milestones in the corresponding fiscal year.

For the performance-based RSAs, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of achieving each individual milestone associated with the award using reasonable assumptions based on the Company's operation performance towards each milestone, (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met and (iv) the Company reassesses the probability of achieving each individual milestone at each reporting date, and any
25
change in estimate is accounted for through a cumulative adjustment in the period when the change in estimate occurs. The non-performance based RSAs and RSUs are valued at the fair value on the grant date and the associated expenses will be recognized over the vesting period.

For the three and nine months ended September 30, 2021, the Company reversed $0.4 million and $0.9 million in noncash stock-based compensation expense related to the performance-based RSAs recognized in previous periods in accordance with the aforementioned expense recognition policy. For the three and nine months ended September 30, 2021, the company recognized an immaterial amount and $2.5 million, respectively, in noncash stock-based compensation expense related to RSAs. For the three and nine months ended September 30, 2020, the Company recognized $0.1 million and $6.5 million, respectively, in noncash stock-based compensation expense related to RSAs and RSUs. As of September 30, 2021, unrecognized noncash stock-based compensation expense related to the unvested RSAs was approximately $3.5 million, the majority of which is related to the performance-based RSAs. The expense recognition for unvested performance-based RSAs is dependent upon the probability of milestone achievement in 2021.

Employee Stock Purchase Plan

On May 7, 2019, the board of directors approved a 2019 Employee Stock Purchase Plan (the 2019 ESPP), which was approved by stockholders at the 2019 annual meeting held on June 5, 2019. The 2019 ESPP initially authorized the issuance of 500,000 shares of common stock pursuant to purchase rights granted to employees. In addition, the number of shares available for issuance under the 2019 ESPP will increase on January 1 of each year in an amount equal to the lesser of (i) 1,000,000 shares, (ii) 2% of the shares of common stock outstanding on December 31, or (iii) such lesser number of shares as is determined by the board of directors. This provision resulted in an additional 1,000,000 shares added to the total number of authorized shares on January 1, 2021. The 2019 ESPP is intended to qualify as an employee stock purchase plan within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended.

The 2019 ESPP enables eligible full-time and part-time employees to purchase shares of the Company’s common stock through payroll deductions of between 1% and 15% of eligible compensation during an offering period. A new offering period begins approximately every June 15 and December 15. At the last business day of each offering period, the accumulated contributions made during the offering period will be used to purchase shares. The purchase price is 85% of the lesser of the fair market value of the common stock on the first or the last business day of an offering period. The maximum number of shares of common stock that may be purchased by any participant during an offering period will be equal to $25,000 divided by the fair market value of the common stock on the first business day of an offering period. The current active offering period under the 2019 ESPP commenced on June 15, 2021 and will end on December 14, 2021. During the three months ended September 30, 2021 and 2020, there were no shares of common stock purchased under the 2019 ESPP. During the nine months ended September 30, 2021 and 2020, there were 173,675 and 67,454 shares of common stock purchased under the 2019 ESPP, respectively.

The fair value of shares to be issued to employees under the 2019 ESPP is estimated using a Black-Scholes option-pricing model at the grant date, which requires the use of subjective and complex assumptions, including (i) the expected stock price volatility, (ii) the calculation of the expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividend yield. The following weighted average assumptions were used in the calculation of fair value of shares under the 2019 ESPP at the grant dates for the period indicated.
Three and Nine Months Ended September 30,
2021 2020
Expected volatility 106.9  % 108.9  %
Risk-free interest rate 0.1  % 0.2  %
Expected dividend yield —  % —  %
Expected term (years) 0.5 0.5


ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The terms “we,” “us,” “our,” “Evofem” or the “Company” refer collectively to Evofem Biosciences, Inc. and its wholly-owned subsidiaries, unless otherwise stated. All information presented in this quarterly report on Form 10-Q (Quarterly Report) is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report. For
26
Table of Contents
additional context with which to understand our financial condition and results of operations, see the audited consolidated financial statements and accompanying notes contained therein as of December 31, 2020 and 2019 and related notes in the Company’s Annual Report on Form 10-K as filed with the SEC on March 4, 2021 (2020 Audited Financial Statements). This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those set forth under Item 1A of Part I of the 2020 Audited Financial Statements. Unless otherwise defined in this section, the defined terms in this section have the meanings set forth in the 2020 Audited Financial Statements.

Overview

We are a San Diego-based commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health.

Our first commercial product, Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel (Phexxi), was approved by the United States (U.S.) Food and Drug Administration (FDA) on May 22, 2020 and commercially launched in the United States in September 2020. Phexxi is the first and only FDA approved hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. We are conducting a pivotal Phase 3 clinical trial to evaluate our lead product candidate, EVO100 (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel (EVO100), for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. We refer to this trial as “EVOGUARD”.

Phexxi: Our Non-hormonal, On-Demand Birth Control

We commercially launched Phexxi in September 2020 with a sales force promoting Phexxi directly to obstetrician/gynecologists and their affiliated health professionals, who collectively write the majority of prescriptions for contraceptive products. Our sales force comprises approximately 69 regional sales representatives and business managers, supported by a self-guided virtual health care provider (HCP) learning platform. Additionally, we offer women direct access to Phexxi via our telehealth platform where women can directly meet with an HCP to determine their eligibility for a Phexxi prescription and potentially have it written by the HCP, filled, and mailed directly to them by a third party pharmacy.

Our comprehensive commercial strategy for Phexxi includes marketing and product awareness campaigns targeting women in the United States of reproductive potential, including the approximately 23 million women who are not using hormonal contraception and the approximately 18.8 million women who are using a prescription contraceptive, some of whom, particularly pill users, may be ready to move to an FDA-approved, non-invasive hormone-free contraceptive, as well as certain identified target HCP segments; payer outreach; and execution of our consumer digital and media strategy.

According to our post-commercial launch market research, HCPs indicated they would recommend Phexxi to approximately 60% of patients who are currently using natural contraceptive methods, approximately 58% of patients who are currently using over-the-counter contraceptive products and approximately 26% of patients who are currently using prescription contraception or methods requiring an HCP to perform a procedure. Additional research into the demographics of more than 1,300 women who are using Phexxi reveals that 60% of Phexxi users are between the ages of 18 to 34 years of age. Among the subset of Phexxi users for whom prior contraceptive data is available (n=413), 39% of women who had recently started Phexxi switched over from either an oral contraceptive, hormone patch/ring, or long-acting reversible contraception.

In December 2020 two U.S. patents that cover Phexxi and its labeled indication were listed in the U.S. FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The Orange Book listing of these two patents covering Phexxi’s composition of matter and its method of use in prevention of pregnancy is an important step in the ongoing development of our patent portfolio, which currently covers Phexxi into 2033. The newly listed method of use patent, number 10,568,855 (the ‘855 patent), covers contraception using the L-lactic acid Phexxi formulation. The ‘855 patent was issued by the U.S. Patent and Trademark Office (USPTO) on February 25, 2020 and is expected to expire in March 2033. The newly listed patent number 6,706,276 (the ‘276 patent) is a composition of matter patent covering Phexxi. Evofem has an exclusive license to this patent, which is held by Rush University Medical Center (Rush University). The ‘276 patent was issued by the USPTO on March 16, 2004 and is expected to expire in March 2026 if the five-year patent term extension (PTE) application that was timely filed by the patent owner is granted. The patents we licensed from Rush University expired in March 2021 outside the United States and are currently set to expire in March 2022 inside the United States pursuant to an Order Granting Interim Extension that extended the expiration of the U.S. patent. In 2020, Rush University submitted a PTE application for the U.S. patent requesting a five-year PTE to 2026. We have not yet been granted the PTE, and there is no assurance that it will be granted for the full five-year term, if at all.

On February 14, 2021, we launched a direct-to-consumer advertising campaign, known as “Get Phexxi,” designed to increase awareness and educate women on the benefits of Phexxi. The campaign highlights some of the struggles women face
27
Table of Contents
when choosing among the many available methods of contraception, including the lack of control with condoms, constant daily use of the pill, and abstinence required for cycle tracking.

On September 9, 2021, we launched a national brand ambassador campaign featuring Emmy® Award-winning celebrity Annie Murphy designed to broaden awareness and drive uptake of Phexxi. We believe early metrics demonstrate that this campaign, called “House Rules,” is effectively reaching our target audience, especially women who are beyond hormones. Through September 30, 2021, the “House Rules” DTC campaign has resulted in a 263% increase in visitors to Phexxi.com, and impacted key metrics including:
•A 71% increase in ex-factory sales of Phexxi (unit shipments to wholesalers) in September versus August 2021.
•More than 5,100 women have begun using Phexxi since the launch of the “House Rules” campaign, driving a 56% increase in new patient starts in September versus August 2021.
•More than 2,800 women booked telehealth visits in the first three weeks of the campaign, a 4x increase over the three-week period pre-launch.
•More than 8,900 Phexxi units were dispensed in September 2021, a 41% increase over the prior month, and total monthly prescriptions grew 45% to 7,839.
•34% increase in new healthcare providers prescribing Phexxi in September versus August 2021. Over 9,400 healthcare providers have written Phexxi since the product launched in September 2020.

We are also collaborating with the National Community Oncology Dispensing Association, Inc. (NCODA), an educational platform for community and academic oncology practices nationwide, to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and availability of Phexxi as a birth control option. Every year in the United States, more than 800,000 new cases of cancer are reported among women, and many cancer treatment protocols require female patients of reproductive potential to use birth control while undergoing treatment. Until the introduction of Phexxi, non-hormonal prescription contraception options were starkly limited; previously, women were generally steered toward condoms or the copper IUD, a prescription medical device that is implanted in the uterus where it releases copper ions and can cause inflammation.

We are working together with NCODA to develop and share resources and educational information for the medically-integrated oncology pharmacy team to help support female cancer patients in deciding which contraceptive option best meets each woman's unique, individual needs. In May 2021, the NCODA published a Positive Quality Intervention (PQI) in connection with Phexxi, and in July 2021, our Chief Executive Officer and Phexxi were featured on NCODA’s PQI Podcast. PQIs are part of the NCODA Quality Standards. These resources are designed to operationalize and standardize practices to achieve positive outcomes for patients. Additionally, our Chief Executive Officer delivered the keynote address at the NCODA 2021 National Spring Forum, and two posters on data sets presenting relevant aspects of the Phase 3 AMPOWER trial evaluating Phexxi were presented at the conference.

We continue working to increase the number of lives covered and to gain preferred formulary position for Phexxi. As of October 2021, 70% of Phexxi prescriptions are being approved either by payers or through Evofem patient support programs. We have coverage for approximately 55% of U.S. commercial lives, including approximately 9 million lives covered at no out-of-pocket cost and approximately 13.7 million lives covered under our December 2020 contract award from the U.S. Department of Veterans Affairs. On January 1, 2021, the U.S. Medicaid population gained access to Phexxi through our participation in the Medicaid National Drug Rebate Program. Medicaid provides health coverage to approximately 68 million members, including approximately 16.8 million women 19-49 years of age.

Phexxi is classified in the databases and pricing compendia of Medi-Span and First Databank, two major drug information databases that payers consult for pricing and product information, as the first and only “Vaginal pH Modulator.”

We continue to work with the FDA’s Office of Women’s Health to update its Birth Control Guide to include a new category for vaginal pH modulators, as the current guide does not have a place for Phexxi due to its unique mechanism of action. We believe this update would require payers (including pharmacy benefit managers) to cover the Phexxi at no cost to patients. We are also working with elected officials in Washington D.C. to encourage updating the guidance regarding contraception coverage, as the guidance has not kept up with innovations like Phexxi. To support those initiatives, we have launched a grassroots coalition that shows the public’s support of the need for updating the chart and guidance.

EVO100: Our STI Preventive Product Candidate

Our lead product candidate, EVO100, is a vaginal gel under evaluation for the prevention of chlamydia and gonorrhea in women - two of the most pervasive sexually transmitted infections (STIs) in the United States. Currently, there are no FDA‑approved prescription products for the prevention of either of these common STIs.

28
Table of Contents
According to the Centers for Disease Control and Prevention (CDC), any sexually active person can be infected with chlamydia or gonorrhea. Despite the CDC recommendation for condom use to prevent STIs, U.S. rates of infection with chlamydia and gonorrhea climbed in 2019 for the sixth consecutive year. Based on these reports, an estimated 78 million women 18-65 years of age who are sexually active in the United States could be at risk to contract these STIs.

Based on the positive and statistically significant top-line results of our Phase 2B/3 AMPREVENCE trial, we initiated our Phase 3 EVOGUARD clinical trial in October 2020. This randomized, placebo-controlled pivotal trial is designed to enroll 1,730 women with a prior chlamydia or gonorrhea infection and who are at risk for future infection. Participants are enrolled for a 16-week interventional phase followed by a one-month follow-up period. We expect to complete enrollment in the first quarter of 2022 and to report top-line EVOGUARD results in the third quarter of 2022. Assuming positive results from the trial, we expect to submit a supplemental New Drug Application for EVO100 in the first quarter of 2023.

The FDA has granted Fast Track designations to EVO100 for the prevention of chlamydia and gonorrhea in women. The FDA has designated EVO100 a Qualified Infectious Disease Product for the prevention of gonorrhea in women, which provides several important potential advantages, including longer market exclusivity.

Financial Operations Overview

Net Product Sales

Our revenue recognition is based on unit shipments from our third-party logistics warehouse to our customers, which consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. We have recognized net product sales in the United States since the commercial launch of Phexxi in September 2020; the quarter ended September 30, 2021 was our fourth full quarter of product sales.

For the quarter ended September 30, 2021, shipments to wholesale distributors and pharmacies grew significantly compared to the quarter ended June 30, 2021, driving an approximate 29% increase in gross revenues. Phexxi outperformed the newer branded contraceptive market over the summer months and the launch of our “House Rules” campaign on September 9, 2021 has increased Phexxi awareness, consideration, and prescriptions. Gross revenues, as discussed in Note 3- Revenue, were adjusted for variable consideration, including our patient support programs.

We intend to out-license commercialization rights for Phexxi to one or more pharmaceutical companies or other qualified potential partners for countries or regions outside of the United States. We are currently in discussion with potential partners for various geographies. We cannot forecast when or if these arrangements will be secured, the structure or potential amount of revenues from these arrangements, whether upfront, milestone-related or related to future Phexxi sales (assuming approval of Phexxi for commercial sale outside of the United States) or to what degree these arrangements would affect our development plans, future revenues and overall capital requirements.

Cost of Goods Sold

The Company began to capitalize the inventory costs associated with Phexxi in April 2020 when it was determined that this inventory had a probable future economic benefit. These inventory costs include all purchased materials, direct labor and manufacturing overhead. Prior to April 2020, costs incurred for the manufacture of Phexxi were recorded as research and development expenses.

In addition, we are obligated to pay quarterly royalty payments pursuant to our license agreement with Rush University, in amounts equal to a single-digit percentage of the gross amounts we receive on a quarterly basis less certain deductions incurred in the quarter based on a sliding scale. We are also obligated to pay a minimum annual royalty amount of $100,000 to the extent these earned royalties do not equal or exceed $100,000 in a given year. A minimum annual royalty amount of $100,000 was first required for the annual period commencing on January 1, 2021. This royalty was approximately $0.1 million and $0.2 million for the three and nine months ended September 30, 2021, respectively, and was included in the costs of goods sold in the condensed consolidated financial statements.

29
Table of Contents
Operating Expenses

Research and development expenses

Our research and development expenses primarily consist of costs associated with the clinical development of EVO100 and costs associated with the continuous improvements related to Phexxi commercialization efforts. These expenses include:
•external development expenses incurred under arrangements with third parties, such as fees paid to clinical research organizations (CROs) relating to our clinical trials, costs of acquiring and evaluating clinical trial data such as investigator grants, patient screening fees, laboratory work and statistical compilation and analysis, and fees paid to consultants;
•costs to acquire, develop and manufacture clinical trial materials, including fees paid to contract manufacturers;
•costs related to compliance with drug development regulatory requirements;
•continuous improvements of manufacturing and analytical efficiency;
•on-going product characterization and process optimization;
•back-up contract manufacturing organization's evaluation to support future commercial forecast and reduce cost of goods sold;
•alternative raw material evaluation to secure an uninterrupted supply chain and reduce cost of goods sold;
•employee-related expenses, including salaries, benefits, travel and noncash stock-based compensation expense; and
•facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and research and other supplies.

We expense internal and third-party research and development expenses as incurred. The following table summarizes research and development expenses by product candidate (in thousands):
Three Months Ended September 30, Nine Months Ended September 30,
  2021   2020 2021 2020
Allocated third-party development expenses:
EVO100 for prevention of chlamydia/gonorrhea- Phase 3 (EVOGUARD) $ 6,890     $ 1,386  $ 17,078  $ 1,529 
EVO100 for prevention of chlamydia/gonorrhea- Phase 2B/3 (AMPREVENCE) —     17  —  (10)
Phexxi for the prevention of pregnancy (AMPOWER) —     2  —  (14)
Total allocated third-party development expenses 6,890     1,405  17,078  1,505 
Unallocated internal research and development expenses:
Noncash stock-based compensation expenses 160  291  1,122  1,689 
Payroll and related expenses 1,048  1,438  3,988  3,539 
Outside services costs 275  705  1,291  3,343 
Other 328  378  991  1,028 
Total unallocated internal research and development expenses 1,811     2,812  7,392  9,599 
Total research and development expenses $ 8,701     $ 4,217  $ 24,470  $ 11,104 

Completion dates and costs for our clinical development programs may vary significantly for EVO100 and any future product candidate we may seek to develop and are difficult to predict. We anticipate that we will determine which programs and product candidates to pursue as well as the most appropriate funding allocations for each program and product candidate on an ongoing basis in response to the results of ongoing and future clinical trials, regulatory developments, and our ongoing assessments of the commercial potential of each current or future product candidate. We expect research and development expenses to increase significantly in 2021 compared to 2020 primarily due to EVOGUARD, which was initiated in October 2020. We will need to raise significant additional capital in the future to complete clinical development for EVO100 and any future product candidates.

The costs of clinical trials may vary significantly over the life of a program owing to the following:

•per patient trial costs;
•the number of sites included in the trials;
•the length of time and level of marketing required to enroll eligible patients;
•the number of patients participating in the trials;
30
Table of Contents
•the number of doses patients receive;
•potential additional safety monitoring or other trials requested by regulatory agencies;
•the phase of development of the product candidate; and
•the efficacy and safety profile of the product candidate.

Selling and marketing expenses

Our selling and marketing expenses consist primarily of Phexxi commercialization costs, including direct-to-consumer (DTC) and HCP advertising, the Phexxi telehealth platform, our sample program, training, salaries, benefits, travel, noncash stock-based compensation expense, and other related costs for our employees and consultants.

We expect our selling and marketing expenses to be significantly higher in 2021 compared to 2020 due to the cost of our sales force, which was established in the third quarter of 2020, and as we continue Phexxi promotional strategies, including all DTC marketing initiatives.

General and administrative expenses

Our general and administrative expenses consist primarily of salaries, benefits, travel, business development expense, investor and public relations expenses, noncash stock-based compensation, and other related costs for our employees and consultants performing executive, administrative, finance, legal and human resource functions. Other general and administrative expenses include facility-related costs not otherwise included in research and development or selling and marketing, and professional fees for accounting, auditing, tax and legal fees, and other costs associated with obtaining and maintaining our patent portfolio.

We expect our general and administrative expenses to decrease slightly in 2021 compared to 2020 due to lower recruiting fees, financing advisory fees, and payroll and related expenses.

Other Income (Expense)

Other income (expense) consists primarily of interest expense and the change in fair value of financial instruments issued in various capital raise transactions. The change in fair value of financial instruments was recognized as a result of mark-to-market adjustments for those financial instruments.

Results of Operations

Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020 (in thousands):

Net Product Sales

Three Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Product sales, net $ 1,712    $ 278  $ 1,434  516  %

Phexxi was commercially launched in September 2020. The increase in product sales, net was primarily due to a full quarter of sales in the current period versus one month of sales in the prior year period, together with continued growth in ex-factory unit sales since commercial launch.

Cost of Goods Sold

Three Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Cost of goods sold $ 955  $ 317  $ 638  201  %

The increase in cost of goods sold was primarily due to a full quarter of sales in the current period versus one month of sales in the prior year period.

31
Table of Contents
Research and development expenses
Three Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Research and development $ 8,701    $ 4,217  $ 4,484  106  %
 
The increase in research and development expenses was primarily due to a $5.5 million increase in clinical trial costs associated with EVOGUARD. This increase was partially offset by a $0.4 million decrease in payroll and related expenses due to lower headcount, a $0.4 million decrease in outside services associated with manufacturing related activities, and a $0.1 million decrease in noncash stock-based compensation.

Selling and marketing expenses
Three Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Selling and marketing $ 30,468  $ 14,700  $ 15,768  107  %

The increase in selling and marketing expenses was primarily due to a $13.8 million increase in media and marketing costs related to ongoing promotional strategies, especially those focused on DTC campaigns that commenced in 2021, a $1.7 million increase in payroll and related expenses due to increased headcount and sales activities in the field, $0.5 million in the Phexxi sample program, and a $0.3 million increase in facilities costs. These aggregated increases were partially offset by a $0.5 million decrease in costs for outside services associated with marketing and medical affairs activities.

General and administrative expenses
Three Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
General and administrative $ 4,957    $ 7,200    $ (2,243) (31) %
    
The decrease in general and administrative expenses was primarily due to a $1.2 million decrease in financing advisory fees and legal fees, a $0.6 million decrease in outside services primarily related to recruiting, a $0.5 million decrease in payroll and related expenses due to lower headcount, and a $0.3 million decrease in noncash stock-based compensation. These aggregated decreases were partially offset by a $0.3 million increase in facilities costs.

Total other income (expense), net
Three Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Total other (expense) income, net $ (30,692) $ (3,741) $ (26,951) 720  %

Total other expense, net, for the three months ended September 30, 2021, primarily included $1.2 million in interest expense related to the convertible senior secured promissory notes issued to Baker Bros. Advisors LP (the Baker Notes) and the unsecured convertible promissory notes issued to each of Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (the Adjuvant Notes) as described in Note 5- Convertible Notes and a $29.5 million loss from the change in fair value of the Baker Notes as a result of mark-to-market adjustments during the current quarter.

Total other expense, net, for the three months ended September 30, 2020, primarily included a $3.1 million loss from the change in fair value of the Baker Notes as a result of mark-to-market adjustments and $0.7 million in accrued interest expense related to the Baker Notes.


32
Table of Contents
Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020 (in thousands):

Net Product Sales

Nine Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Product sales, net $ 4,674  $ 278  $ 4,396  1,581  %

Phexxi was commercially launched in September 2020. The increase in product sales, net was primarily due to a full nine months of sales in the current period versus one month of sales in the prior year period, continued growth in ex-factory unit sales since commercial launch, and an increase in both gross and net sales from the impact of Phexxi promotional strategies and gross-to-net initiatives implemented since commercial launch.

Cost of Goods Sold

Nine Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Cost of goods sold $ 2,300  $ 317  $ 1,983  626  %

The increase in cost of goods sold was primarily due to a full nine months of sales in the current period versus one month of sales in the prior year period.

Research and development expenses
Nine Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Research and development $ 24,470  $ 11,104  $ 13,366  120  %
 
The increase in research and development expenses was primarily due to a $15.4 million increase in clinical trial costs associated with EVOGUARD, and a $0.5 million increase in payroll and related expenses due to increased headcount to support clinical and regulatory activities. These aggregated increases were partially offset by a $1.9 million decrease in outside services associated with manufacturing and regulatory related activities and a $0.6 million decrease in noncash stock-based compensation.

Selling and marketing expenses
Nine Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Selling and marketing $ 88,230  $ 32,553  $ 55,677  171  %

The increase in selling and marketing expenses was primarily due to a $45.3 million increase in media and marketing costs related to ongoing promotional strategies especially those focused on DTC campaigns that commenced in 2021, a $9.7 million increase in payroll and related expenses due to increased headcount and sales activities in the field, $1.7 million in the Phexxi sample program, and a $1.7 million increase in facilities costs. These aggregated increases were partially offset by a $2.8 million decrease in costs for outside services associated with marketing, market access and medical affairs activities, and a $0.4 million decrease in noncash stock-based compensation.

General and administrative expenses
Nine Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
General and administrative $ 19,057  $ 24,077  $ (5,020) (21) %
    
The decrease in general and administrative expenses was primarily due to a $2.6 million decrease in noncash stock-based compensation, a $1.9 million decrease in financial and recruiting related outside services, a $1.4 million decrease in financing advisory fees and legal fees, and a $0.3 million decrease in payroll and related expenses due to lower headcount. These aggregated decreases were partially offset by a $1.0 million increase in facilities costs.

33
Table of Contents
Total other income (expense), net
Nine Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Total other (expense) income, net $ (24,244) $ (33,936) $ 9,692  (29) %

Total other expense, net, for the nine months ended September 30, 2021, primarily included $3.5 million in interest expense related to the Baker Notes and the Adjuvant Notes as described in Note 5- Convertible Notes and a $20.7 million loss from the change in fair value of the Baker Notes as a result of mark-to-market adjustments in the first half of 2021.

Total other expense, net, for the nine months ended September 30, 2020, mainly included a $64.0 million loss on issuance of convertible notes, warrants and purchase rights issued in connection with the Baker Notes, and $1.0 million in accrued interest expense related to the Baker Notes and the Adjuvant Notes. This loss was partially offset by a $31.0 million gain from the change in fair value of the Baker Notes as a result of mark-to-market adjustments.

Liquidity and Capital Resources

Overview

As of September 30, 2021, we had a working capital deficit of $39.8 million and an accumulated deficit of $809.1 million. We have financed our operations to date primarily through the issuance of common stock and warrants, cash received from private placement transactions, the issuance of convertible notes and, to a lesser extent, product sales. As of September 30, 2021, we had approximately $14.9 million in cash and cash equivalents, and $9.0 million in restricted cash from the Adjuvant Notes that is available for use. Our cash and cash equivalents include amounts held in checking accounts, money market funds, and investments in fixed income debt securities with original maturities of less than three months. We invest cash in excess of immediate requirements in accordance with our investment policy, which limits the amounts we may invest in any one type of investment and requires all investments held by us to maintain minimum ratings from Nationally Recognized Statistical Rating Organizations so as to primarily achieve liquidity and capital preservation.

We have incurred losses and negative cash flows from operating activities since inception. During the nine months ended September 30, 2021, we received net proceeds of approximately $81.5 million upon the sale and issuance of common stock and warrants to purchase common stock from two underwritten public offerings that occurred in March and May of 2021. In October 2021, we received net proceeds of approximately $9.7 million from a registered direct offering.

We anticipate that we will continue to incur net losses for the foreseeable future. We expect research and development expenses to be significantly higher in 2021 compared to 2020 due to our Phase 3 EVOGUARD study, which was initiated in October 2020. We expect selling and marketing expenses to increase significantly in 2021 compared to 2020 due to the deployment of our commercial sales force that was established in the third quarter of 2020 and as we execute associated promotional strategies and initiatives, including our DTC programs. Lastly, we expect general and administrative expenses to decrease slightly in 2021 compared to 2020 due to lower recruiting fees and financing advisory fees.

We currently expect our liquidity resources as of September 30, 2021 together with the net proceeds of the registered direct offering completed in October 2021, to be sufficient to fund our planned operations into the first quarter of 2022. The uncertainties associated with our ability to obtain additional equity financing on terms that are favorable to us or at all, enter into collaborative agreements with strategic partners, and succeed in our future operations raise substantial doubt about our ability to continue as a going concern. In addition, the COVID-19 pandemic caused us to delay the commercial launch of Phexxi until September 2020. Also, due in part to the impact of the COVID-19 pandemic, the completion of enrollment in the Phase 3 EVOGUARD study is now expected in the first quarter of 2022 and we expect to report top-line EVOGUARD results in the third quarter of 2022. Our ability to raise additional funds, and the terms on which those funds may be raised, will be dependent, in part, on how successful the commercialization of Phexxi is, whether we are able to gain revenue traction prior to raising such additional funds, and the success of our research and development efforts, including our ability to develop EVO100. If the COVID-19 pandemic continues to disrupt and negatively impact the commercialization of Phexxi or our research and development efforts, our ability to raise additional funds may be negatively impacted, or we may not be able to obtain funding on terms favorable to us or at all.

If we are not able to obtain required additional funding when and as needed, through equity financings or other means, or if we are unable to obtain funding on terms favorable to us, the shortfall in funds raised, or such unfavorable terms, will likely have a material adverse effect on our operations and strategic plan for future growth. If we cannot successfully raise the funding necessary to implement our current strategic plan, we may be forced to make reductions in spending, suspend or terminate development programs, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs, and/or cease operations. Any of these developments would materially and adversely affect our financial
34
Table of Contents
condition and business prospects and could even cause us to be unable to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and, in doing so, we may receive less than the value at which those assets are carried on our financial statements. Any of these developments would materially and adversely affect the price of our stock and the value of your investment.

The opinion of our independent registered public accounting firm on our audited financial statements as of and for the years ended December 31, 2020 and 2019 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Future reports on our financial statements may include an explanatory paragraph with respect to our ability to continue as a going concern. Our unaudited condensed consolidated financial statements as of September 30, 2021 and for three and nine months ended September 30, 2021 and 2020 included in this Quarterly Report do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should we be unable to continue our operations.

2021 Equity Financings

As described in Note 10- Stockholders' Equity (Deficit), we received proceeds of approximately $28.0 million, net of underwriting discounts, from a public offering in March 2021, upon the issuance of 17,142,857 shares of our common stock, and approximately $4.2 million, net of underwriting discounts, from the issuance of 2,571,428 shares of common stock upon exercise of the underwriters’ overallotment option in April 2021.

As described in Note 10- Stockholders' Equity (Deficit), we received proceeds of approximately $46.8 million, net of underwriting discounts and fees, from a public offering in May 2021, upon the issuance of 50,000,000 shares of common stock and common warrants to purchase 50,000,000 shares of common stock. We received approximately $2.4 million and $0.1 million, both net of underwriting discounts, from the issuance of 2,547,794 shares of common stock and 7,500,000 common warrants, respectively, upon exercise of the underwriter’s overallotment option in May 2021.

As described in Note 10- Stockholders' Equity (Deficit), we received proceeds of approximately $9.7 million, net of offering expenses, from a registered direct offering in October 2021, upon the issuance of 5,000 shares of Series B-1 Convertible Preferred Stock and 5,000 shares of Series B-2 Convertible Preferred Stock.

2020 Debt and Equity Financing

As described in Note 5- Convertible Notes, we received aggregate gross proceeds of $25.0 million upon the first and second closings of convertible senior secured promissory notes pursuant to the Securities Purchase and Security Agreement with certain affiliates of Baker Bros. Advisors LP as purchasers during the second quarter of 2020. We also received gross proceeds of $25.0 million from the closing of convertible unsecured promissory notes pursuant to the Adjuvant Purchase Agreement during the fourth quarter of 2020.

As described in Note 10- Stockholders' Equity (Deficit), we received net aggregate proceeds of $103.7 million in June 2020 upon the issuance and sale of 31,700,000 shares of our common stock from our 2020 Public Offering and net aggregate proceeds of $3.8 million during the first half of 2020 upon the issuance and sale of 676,656 shares of our common stock pursuant to the “at the market” (ATM) program. The ATM program was terminated in June 2020.

Summary Statement of Cash Flows

The following table sets forth a summary of the net cash flow activity for each of the periods set forth below (in thousands): 
  Nine Months Ended September 30, 2021 vs. 2020
  2021 2020 $ Change % Change
Net cash, cash equivalents and restricted cash used in operating activities $ (125,402) $ (65,750) $ (59,652) 91  %
Net cash, cash equivalents and restricted cash (used in) provided by investing activities (2,636) 7,650  (10,286) (134) %
Net cash, cash equivalents and restricted cash provided by financing activities 80,827  129,309  (48,482) (37) %
Net (decrease) increase in cash, cash equivalents and restricted cash $ (47,211) $ 71,209  $ (118,420) (166) %

Cash Flows from Operating Activities. During the nine months ended September 30, 2021 and 2020, the primary use of cash, cash equivalents and restricted cash was to fund commercialization of our lead product Phexxi, to fund the Phase 3
35
Table of Contents
clinical trial to evaluate our lead product candidate EVO100, and to support selling and marketing and general and administrative operations.

Cash Flows from Investing Activities. During the nine months ended September 30, 2021, the change in net cash, cash equivalents and restricted cash used in investing activities was primarily due to $2.9 million in purchases of property and equipment, offset by a $0.3 million cash inflow from the sale of Softcup line of business. During the nine months ended September 30, 2020, the change in net cash, cash equivalents and restricted cash provided by investing activities was primarily due to an $8.2 million cash inflow from maturities of short-term investments, offset by $0.8 million in purchases of property and equipment.

Cash Flows from Financing Activities. During the nine months ended September 30, 2021, the primary source of cash, cash equivalents and restricted cash was provided from the issuance of 72,262,079 shares of common stock and 7,500,000 shares of common warrants for proceeds of approximately $81.5 million, net of underwriting discounts, the issuance of 173,675 shares of our common stock under the 2019 ESPP with proceeds of approximately $0.2 million, the issuance of 159,000 shares of common stock from the exercise of common warrants for proceeds of approximately $0.2 million, offset by $0.3 million in payments of tax withholdings related to vesting of restricted stock awards and $0.7 million in payments for financing issuance costs.

During the nine months ended September 30, 2020, the primary source of cash, cash equivalents and restricted cash was the sale of 31,700,000 shares of common stock for proceeds, net of underwriting commissions, of approximately $103.7 million, gross proceeds of $25.0 million from issuance of convertible notes and warrants, the sale of 676,656 shares of common stock under the ATM program for proceeds of approximately $3.8 million in cash and cash equivalents, net of commissions, the issuance of 89,106 shares of our common stock under the 2019 ESPP and exercise of stock options with proceeds of approximately $0.3 million, offset by $2.9 million in payments of tax withholdings related to vesting of restricted stock awards and $0.9 million payments for financing and debt issuance costs.

Operating and Capital Expenditure Requirements

Our specific future operating and capital expense requirements are difficult to forecast, however, we can anticipate the general types of expenses and areas in which they might occur as follows: we expect research and development expenses and selling and marketing expenses to increase significantly in 2021, while we expect general and administrative expenses to decrease slightly in 2021 due to the reasons stated under the Operating Expenses section above.

Off-Balance Sheet Arrangements

As of September 30, 2021 and December 31, 2020, we did not have any off-balance sheet arrangements, as that term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Other Matters

Recently Issued Accounting Pronouncements

For information with respect to recent accounting pronouncements, see Note 2- Summary of Significant Accounting Policies to our condensed consolidated financial statements appearing in Part I, Item 1 of this report.

Critical Accounting Policies

Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the applicable periods. Management bases its estimates, assumptions and judgments, on historical experience and on various other factors it believes to be reasonable under the circumstances. Different estimates, assumptions and judgments may change the estimate used in the preparation of our condensed consolidated financial statements, which, in turn, could materially change our results from those reported. Management evaluates its estimates, assumptions and judgments on an ongoing basis. However, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material adverse effect on our consolidated statements of operations, liquidity and financial condition. We believe the following critical accounting policies involve significant areas where management applies estimates, assumptions and judgments in the
36
Table of Contents
preparation of our condensed consolidated financial statements. See Note 2- Summary of Significant Accounting Policies to our 2020 Audited Financial Statements for our additional accounting policies.

Revenue Recognition and Trade Accounts Receivable

The Company recognizes revenue from the sale of its product Phexxi in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) Identify the contract(s) with a customer; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to the performance obligations in the contract; (5) recognize revenue when (or as) the entity satisfies a performance obligation.

In accordance with ASC 606, the Company recognizes revenue when its performance obligation is satisfied by transferring control of the product to a customer. Per the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. Payment terms typically range from 45 to 66 days, include prompt pay discounts, and vary by customer. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances.

The amount of revenue recognized by the Company is equal to the amount of consideration which is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine the amount of revenue to recognize, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue.

Phexxi is sold to customers at the wholesale acquisition cost (WAC), or in some cases at a discount to WAC. However, the Company records product revenue, net of estimates for applicable variable consideration.

Clinical Trial Accruals

As part of the process of preparing our financial statements, we are required to estimate expenses resulting from our obligations under contracts with vendors, CROs and consultants and under clinical site agreements relating to conducting our clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.

Our objective is to reflect the appropriate clinical trial expenses in our condensed consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. We account for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models and discussions with applicable personnel and outside service providers as to the progress of clinical trials.

During a clinical trial, we adjust the clinical expense recognition if actual results differ from estimates. We make estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. Our clinical trial accruals are partially dependent upon accurate reporting by CROs and other third-party vendors. Although we do not expect estimates to differ materially from actual amounts, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any reporting period. For the three and nine months ended September 30, 2021 and 2020, there were no material adjustments to our prior period estimates of accrued expenses for clinical trials.

Fair Value of the Baker Notes

We elected the fair value option under ASC 825, Financial Instruments, for the Baker Notes issued pursuant to that certain Baker Bros. Purchase Agreement with the Baker Purchasers, and Baker Bros. Advisors LP, as designated agent, dated April 23, 2020, as they are qualified financial instruments and are, in whole, classified as liabilities. Under the fair value option, we recognized the hybrid debt instrument at fair value inclusive of embedded features. The fair value of the Baker Notes issued, and the change in fair value of the Baker Notes at the reporting date, were determined using a Monte Carlo simulation-based model. Monte Carlo simulation was used to take into account several embedded features and factors including the future value of our common stock, a potential change of control event, the probability of meeting certain debt covenants, the maturity term of the Baker Notes, the probability of an event of voluntary conversion of the Baker Notes, exercise of the put right, and exercise of our call right. The mark-to-market adjustment for the quarter ended September 30, 2021 in the condensed consolidated financial statements was in consideration of the increased probability of the failure to meet certain affirmative debt covenants and thus paying a higher repurchase price.

37
Table of Contents
Fair Value of Stock Options and Warrants

The fair value of stock options and warrants issued in various financing transactions, the change in fair value of options and warrants as a result of any modifications to these instruments, and mark-to-market adjustments for liability classified warrants were determined using the Black-Scholes Merton option-pricing model based on the applicable assumptions, which include the exercise price of these options and warrants, time to expiration, expected volatility of our peer group of companies, risk-free interest rate and expected dividend.

Fair Value of Purchase Rights

The fair value of the rights granted to the Baker Purchasers to optionally purchase from the Company up to $10.0 million of Baker Notes, as described in Note 5- Convertible Notes, at the Baker Purchasers’ discretion at any time prior to the Company receiving at least $100.0 million in aggregate gross proceeds from one or more sales of equity securities issued in connection with the Baker Bros. Purchase Agreement, as described in Note 5- Convertible Notes, and the change in fair value of the Baker Purchasers’ option to purchase from the Company up to $10.0 million of Baker Notes upon exercise of such rights, was determined as the maximum of (i) the fair value of rights to purchase the additional $10.0 million Baker Notes and; (ii) the fair value of the shares of on as-if converted basis, which was determined by the lattice model. The fair value of rights to purchase the accompanying 2,049,180 warrants was valued using a Geske option-pricing model. The Geske model was based on the applicable assumptions, including the underlying stock price, warrant exercise price, the exercise price of the rights to purchase the warrants, the term of the warrants, the term of the rights to purchase the warrants, expected volatility of the Company’s peer group, risk-free interest rate and expected dividend.

Inventories

Inventories, consisting of purchased materials, direct labor and manufacturing overheads, are stated at the lower of cost, or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. At each balance sheet date, we evaluate ending inventories for excess quantities, obsolescence, or shelf-life expiration. The evaluation includes an analysis of our current and future strategic plans, anticipated future sales, the price projections of future demand, and the remaining shelf life of goods on hand. To the extent that we determine there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for us to reasonably expect that it can sell those products prior to their expiration, we adjust the carrying value to estimated net realizable value.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. As of the end of the period covered by this quarterly report on Form 10-Q, our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on such evaluation, our principal executive officer and principal financial officer has concluded that, as of such date, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.




38
Table of Contents
Inherent Limitations of Internal Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we may be involved in various disputes and litigation matters that arise in the ordinary course of business. We are currently not a party to any material legal proceedings.

Item 1A. Risk Factors

Except for the risk factors set forth below, there have not been any material changes to the risk factors disclosed in our Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 4, 2021.

We will need to raise significant additional funds to finance our operations, including the commercialization of Phexxi and our development of EVO100, and to remain a going concern. If we are unable to raise additional capital when needed or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our business initiatives.

We have incurred significant losses and negative cash flows since our inception. We believe our existing capital resources, including the net proceeds from the issuance and sale of shares of our Series B-1 Convertible Preferred Stock and B-2 Convertible Preferred Stock in October 2021, will be sufficient to sustain our planned operations into the first quarter of 2022. Our ability to raise additional funds will depend, in part, on our ability to successfully commercialize Phexxi in the United States and to successfully develop EVO100 in a timely manner. If, for whatever reason, we are unable to gain traction in the market for Phexxi or fail to successfully develop EVO100, it may make any necessary debt, equity or alternative financing more difficult, more costly and more dilutive.

Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to commercialize Phexxi or develop our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. In certain situations, we are also currently prohibited from raising additional debt financing without the consent of the holders of our outstanding convertible notes. Furthermore, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise additional funds when needed or on acceptable terms, we may be unable to commercialize Phexxi as a contraceptive or to continue the development of EVO100. In addition, we may be required to delay, scale back or eliminate some or all of our other development programs and business initiatives, or be forced to cease operations entirely. To the extent we raise additional capital through the sale of equity, convertible debt or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Future debt financings, if available at all, would likely involve agreements with additional covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions or declaring dividends. If we raise additional funds through strategic collaborations, alternative non-dilutive financing, such as royalty-based financing, or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. Moreover, if we are unable to continue as a going concern, we may be forced to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. Given the liquidation preference owed to holders of our Series B-2 Convertible Preferred Stock and amounts currently owed pursuant to the Adjuvant Notes and the Baker Notes, holders of our common stock may not receive value for their shares in the event of a liquidation.
39
Table of Contents

We have certain obligations pursuant to our issued and outstanding convertible notes and related note purchase agreements, and our failure to comply with these obligations could have a material adverse effect on our business, financial condition or results of operations.

In April 2020, we entered into the Baker Bros. Purchase Agreement with certain institutional investors and their designated agent pursuant to which we issued and sold secured convertible promissory notes in an aggregate principal amount of $25.0 million and warrants to purchase shares of our common stock. In October 2020, we entered into the Adjuvant Purchase Agreement pursuant to which we issued and sold to certain institutional investors unsecured convertible promissory notes in an aggregate principal amount of $25.0 million. Our failure to make payments as due under these notes would likely amount to an event of default. Pursuant to the terms of the Baker Bros. Purchase Agreement and the Adjuvant Purchase Agreement, events of default also include, but are not limited to, a material breach of representations, our failure to comply with our obligation to convert the related promissory notes, certain defaults of indebtedness and failure to perform or observe, and in certain instances, cure, certain covenants, including, but not limited to, covenants requiring us to maintain the listing of shares of our common stock on the Nasdaq Capital Market and to achieve cumulative net sales of Phexxi of at least $100.0 million by June 30, 2022. These agreements also limit our ability to incur debt, merge or, declare dividends. In particular and pursuant to the Baker Bros. Purchase Agreement, if an event of default occurs, each purchaser could elect, at its option pursuant to the agreement, to require us to repurchase all or any portion of the notes in cash at a repurchase price equal to the sum of (i) three times the sum of the outstanding balance, plus (ii) the aggregate value of future interest that would have accrued under the call principal amount from the period commencing on the date on which this amount is declared to be due and payable through the fifth anniversary of the initial closing pursuant to the Baker Bros. Purchase Agreement. This repurchase would materially and adversely impact our business, results of operations and financial condition, as well as increase our need to raise additional capital.

Our shares of common stock could be delisted from the Nasdaq Capital Market which could result in, among other things, a decline in the price of our common stock and less liquidity for holders of shares of our common stock.

Our common stock is listed on the Nasdaq Capital Market, which imposes, among other requirements, a minimum $1.00 per share bid price requirement for continued inclusion on The Nasdaq Capital Market pursuant to the Bid Price Requirement. The closing bid price for our common stock must remain at or above $1.00 per share to comply with the Bid Price Requirement for continued listing. Since July 12, 2021, the closing bid price for our common stock has been below $1.00 per share. On August 23, 2021, we received a deficiency letter from the Staff of Nasdaq notifying us, that, for the preceding 30 consecutive trading days, the closing bid price for shares of our common stock was below the minimum $1.00 per share requirement and that we had failed to comply with the Bid Price Requirement.

In accordance with Nasdaq rules, we have been provided until the Compliance Date to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for shares of our common stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide us written confirmation of compliance with the Bid Price Requirement. If we do not regain compliance with the Bid Price Requirement by the Compliance Date, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Requirement, and would need to provide written notice of our intention to cure the deficiency during the second 180 calendar day compliance period, by effecting a reverse stock split, if necessary. If we do not regain compliance with the Bid Price Requirement by the Compliance Date and are not eligible for the additional 180 calendar day compliance period at that time, the Staff will provide written notification to us that shares of our common stock will be subject to delisting. At that time, we may appeal the Staff’s delisting determination to a Nasdaq Hearing Panel. There can be no assurance that we will regain compliance with the Bid Price Requirement within any compliance period, we will be eligible for an additional 180 calendar day compliance period, any appeal to the Nasdaq Hearing Panel will be successful or that we will otherwise maintain compliance with any of the other Nasdaq listing requirements.

Delisting from the Nasdaq Capital Market could make trading our common stock more difficult for investors, potentially leading to declines in our share price and liquidity. If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system, where an investor may find it more difficult to sell our stock or obtain accurate quotations as to the market value of our common stock. Other consequences could include: adversely affecting our ability to obtain equity financing at acceptable terms, a negative effect on the common stock trading volume, price, and an increase in the stock volatility, and a possible loss of confidence by shareholders, employees, and business partners. We cannot ensure that our common stock, if delisted from the Nasdaq Capital Market, will be listed on another national securities exchange or quoted on an over-the counter quotation system. As noted above, our failure to maintain the listing of our common stock on the Nasdaq Capital Market would also likely be an event of default under the Baker Bros. Purchase Agreement.

40
Table of Contents
We have a limited number of shares of common stock available for future issuance which could adversely affect our ability to raise capital or consummate strategic transactions.

We are currently authorized to issue 300 million shares of common stock under our amended and restated certificate of incorporation. As of October 31, 2021, we have issued 163,144,964 shares of common stock and approximately 96,919,504 shares of common stock were committed for issuance giving effect to the assumed exercise of all outstanding warrants and options and the assumed conversion of all issued and outstanding convertible notes as of this date. As of this date, we were also required to reserve 12,500,000 shares of common stock for issuance upon conversion of outstanding shares of Series B-2 Convertible Preferred Stock. Due to the limited number of authorized shares common stock available for future issuance, we may not able to raise additional equity capital or complete a merger or other business combination unless we increase the number of shares we are authorized to issue. We are seeking stockholder approval to increase the number of our authorized shares of common stock at a special meeting of our stockholders to be held on December 8, 2021, and we can provide no assurance that we will succeed in obtaining the requisite approval to amend our amended and restated certificate of incorporation to increase the number of shares of common stock we are authorized to issue which could negatively impact our business, prospects and results of operations or ultimately cause us to have to cease operations entirely.

The Series B-2 Convertible Preferred Stock has rights, preferences and privileges that are not be held by, and are preferential to, the rights of holders of our common stock, which could adversely affect the liquidity and financial condition of the Company, and may result in the interests of the holders of Series B-2 Convertible Preferred Stock differing from those of the holders of our common stock. Any issuance of our common stock upon conversion of the Series B-2 Convertible Preferred Stock will cause dilution to holders of our common stock and may depress the market price of our common stock.

The Series B-2 Convertible Preferred Stock ranks senior to the holders of shares of our common stock with respect to liquidation preferences. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series B-2 Convertible Preferred Stock will be entitled to receive distributions out of our assets in an amount per share equal to $1,000 per share (or approximately $5 million as of October 31, 2021), before any distributions shall be made on any shares of our common stock. In addition and following October 26, 2025, holders of Series B-2 Convertible Preferred Stock are entitled to request redemption of their shares of Series B-2 Preferred Stock at the price of $1,000 per share. These preferential rights could result in divergent interests between the holders of shares of Series B-2 Convertible Preferred Stock and the holders of our common stock. Shares of Series B-2 Convertible Preferred Stock are also convertible into shares of our common stock (subject to typical beneficial ownership and Nasdaq 19.99% limitations). Shares of common stock issued upon conversion of the Series B-2 Convertible Preferred Stock will cause dilution to holders of our common stock. The conversion price per share for shares of our Series B-2 Convertible Preferred Stock is the greater of $0.60 or the price computed as the product of 0.85 multiplied by the arithmetic average of the closing sale prices of a per share of our common stock during the five consecutive trading-day period immediately preceding the conversion date. Until late April 2022, this conversion price is also subject to full ratchet adjustment for certain dilutive issuances. This conversion price and the shares issuable upon conversion of shares of Series B-2 Convertible Preferred Stock may depress the market price of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Common Stock Purchases

The table below is a summary of purchases of our common stock we made during the quarter covered by this report. Other than as indicated in the table below, no such purchases were made in any other month during the quarter. We do not have any publicly announced repurchase plans or programs.
Period Total Number of Shares Purchased (1) Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares That May Yet be Purchased Under the Plans or Programs
July 1- July 31 19,998 $0.98 — —
(1) These shares were surrendered to the Company to satisfy tax withholdings obligations in connection with the vesting of restricted stock awards.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.
41
Table of Contents

Item 5. Other Information

Effective November 15, 2021, Russell Barrans will retire as the Company’s chief commercial officer. In connection with Mr. Barrans’ retirement, on November 12, 2021, the Company entered into a separation agreement with Mr. Barrans (the Barrans Separation Agreement). The Barrans Separation Agreement includes a customary release of claims against the Company that are or may be held by Mr. Barrans and entitles Mr. Barrans to (i) a severance payment equal to $511,290, which represents twelve months in value of Mr. Barrans’ base salary and is payable, at the Company’s election, in a lump sum or by normal payroll until February 28, 2022 and (ii) a prorated performance bonus for fiscal year 2021, to be determined by the Compensation Committee, which is payable no later than March 15, 2022. The foregoing description of the Barrans Separation Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the Barrans Separation Agreement filed as Exhibit 10.2 to this report and incorporated by reference herein.
42
Table of Contents
Item 6. Exhibits

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index.

EXHIBIT INDEX
Exhibit
No.
Exhibit Title
Filed
Herewith
Incorporated by Reference
Form
File No.
Date Filed
3.1 X
10.1^  Securities Purchase Agreement, dated October 11, 2021 8-K 001-36754 October 12, 2021
10.2 X
31.1 X
31.2 X
32.1* X
101.INS† XBRL Instance Document X
101.SCH† XBRL Taxonomy Extension Schema Document X
101.CAL† XBRL Taxonomy Extension Calculation Linkbase Document X
101.DEF† XBRL Definition Linkbase Document X
101.LAB† XBRL Taxonomy Extension Labels Linkbase Document X
101.PRE† XBRL Taxonomy Extension Presentation Linkbase Document X
^ Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.
*
Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing.
†
The financial information of Evofem Biosciences, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed on November 15, 2021 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Operations, (iv) the Condensed Consolidated Statements of Stockholders’ Equity (Deficit), (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Unaudited Condensed Consolidated Financial Statements, is furnished electronically herewith.
43
Table of Contents
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
EVOFEM BIOSCIENCES, INC.
Date: November 15, 2021 By: /s/ Justin J. File
Justin J. File
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)



44
Delaware The First State Page 1 4055778 8100X Authentication: 204644525 SR# 20213749624 Date: 11-09-21 You may verify this certificate online at corp.delaware.gov/authver.shtml I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS FILED FROM AND INCLUDING THE RESTATED CERTIFICATE OR A MERGER WITH A RESTATED CERTIFICATE ATTACHED OF “EVOFEM BIOSCIENCES, INC.” AS RECEIVED AND FILED IN THIS OFFICE. THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED: RESTATED CERTIFICATE, FILED THE TWENTY-FOURTH DAY OF NOVEMBER, A.D. 2014, AT 1:30 O`CLOCK P.M. CERTIFICATE OF AMENDMENT, CHANGING ITS NAME FROM "NEOTHETICS, INC." TO "EVOFEM BIOSCIENCES, INC.", FILED THE SEVENTEENTH DAY OF JANUARY, A.D. 2018, AT 11:17 O`CLOCK A.M. CERTIFICATE OF CHANGE OF REGISTERED AGENT, FILED THE ELEVENTH DAY OF MARCH, A.D. 2019, AT 3:42 O`CLOCK P.M. CERTIFICATE OF DESIGNATION, FILED THE TWENTY-FOURTH DAY OF MARCH, A.D. 2020, AT 4:30 O`CLOCK P.M. CERTIFICATE OF DESIGNATION, FILED THE ELEVENTH DAY OF OCTOBER, A.D. 2021, AT 12:30 O`CLOCK P.M.

 
Delaware The First State Page 2 4055778 8100X Authentication: 204644525 SR# 20213749624 Date: 11-09-21 You may verify this certificate online at corp.delaware.gov/authver.shtml CERTIFICATE OF DESIGNATION, FILED THE ELEVENTH DAY OF OCTOBER, A.D. 2021, AT 12:31 O`CLOCK P.M.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Exhibit 10.2
CONFIDENTIAL EMPLOYMENT TRANSITION PLAN AND GENERAL RELEASE AGREEMENT
This Confidential Employment Transition Plan and General Release Agreement (“Agreement”) is made and entered into by and between Evofem Biosciences, Inc. (“Evofem” or the “Company”) and Russell Barrans (“Executive”). In this Agreement, Company and Executive will be referred to collectively as the “Parties” and individually as a “Party.” This Agreement shall not become effective or enforceable until the Parties have both signed this Agreement, and until after the revocation period referenced in Section 4.2 has expired (hereinafter the “Effective Date”).
1.     RECITALS
1.1WHEREAS Executive is a current Evofem employee, in an Executive capacity, namely Company’s Chief Commercial Officer,
1.2WHEREAS there is a July 2, 2018 Executive Employment Agreement (“Employment Agreement”) in effect between the Parties and it is the intent of the Parties to leave that Employment Agreement in effect except as expressly amended by this Agreement,
1.3WHEREAS the Parties wish to formalize an employment transition plan that would accommodate the mutual desire for Executive to retire and separate from the Company as of November 15, 2021 (the “Separation Date”).
Accordingly, the Parties agree as follows:
2.PAYMENT AND PROMISES.
2.1Recitals. This Agreement incorporates the Recitals in Section 1 as if fully set forth herein.
2.2Consideration by Company. In consideration of this Agreement, Company agrees to the following:

(a)Company shall treat the separation as having occurred pursuant to Section 4(e) of the Employment Agreement.
(b)Company will provide all consideration required under Section 4(e) of the Employment Agreement with the following amendments: (i) no Equity Acceleration pursuant to Section 4(e)(iii). In exchange for foregoing said Equity Acceleration, Company shall extend the exercise period by 12 months for any stock options vested as of the Separation Date; (ii) the Severance Payment provided by Section 4(e)(i) may be made, at the Company’s election, either in one lump sum on the Separation Date or by normal payroll until Feb 28, 2022 and the remainder due at that time in a lump sum; and (iii) Pro Rata

1 of 13

Bonus as described in Section 4(e)(ii) shall be on the terms and with the timing specified in Section 3(b).
(c)In addition to the payments required under the Employment Agreement, if Company, in its sole discretion, determines that Executive has: (i) remained retired from full time employment for two years following the Separation Date; (ii) and remained otherwise in complete compliance with this Agreement and with the Employment Agreement for two years following the Separation Date; and (iii) has continued to assist Evofem’s designated Investor Relations consultant in responding to negative posts on social media (using Executive’s personal phone and e-mail to do so) for one year following the Separation Date, then Company shall make an additional payment of $100,000 to Executive within ten days of the two year anniversary of the Separation Date. Such additional payment shall be on a 1099 basis with no withholding for taxes, all of which shall be the responsibility of Executive.

3.RELEASE, COVENANTS, AND REPRESENTATIONS
3.1Release. In exchange for the promises in this Agreement (including the consideration identified in Section 2, Executive releases and discharges Company and its successors, subsidiaries, parents, predecessors, affiliates, and divisions, and their respective insurers, reinsurers, shareholders, owners, employees, officers, directors, assigns, agents, representatives and attorneys (collectively, the “Releasees”) from any and all claims, demands, arbitrations, actions, suits, orders, proceedings, damages, debts, liabilities, obligations, remedies (including statutory remedies), wages, benefits, penalties, existing and future liens, and causes of action of every kind and nature, whether known or unknown, suspected or unsuspected, anticipated or unanticipated, that Executive now has, or at any time ever had, against the Releasees, including without limitation:
(a)    That were or could have been alleged with respect to any aspect of Executive’s work at Company or with respect to any interactions between Executive and his co-workers and supervisors that occurred as of the date of Executive’s execution of this Agreement;
(b)    That were, or could have, been based on, arising from, or relating in any way to any anti-discrimination statutes, such as Title VII of the Civil Rights Act of 1964, which prohibits race, color, religion, sex and national origin discrimination in employment; the California Fair Employment and Housing Act, which prohibits race, color, religion, sex, age, disability and national origin

2 of 13

discrimination; the Americans With Disabilities Act, which prohibits discrimination against individuals with disabilities; the Family and Medical Leave Act, which prohibits discrimination based against individuals needing family or medical leave; the California Family Rights Act, which prohibits discrimination against individuals needing family or medical leave; the Age Discrimination in Employment Act, the Genetic Information Nondiscrimination Act of 2008, the Family and Medical Leave Act of 1993, the Employee Retirement Income Security Act of 1974, COBRA, and any similar California or other state or local statute or ordinance;
(c)    That were, or could have been, based on, arising from, or relating in any way to any other laws such as the California Labor Code and the Fair Labor Standards Act, which regulate wages, hours and working conditions, including but not limited to any and all claims for alleged failure to provide commissions and/or bonus, and any and all related penalties and interest pertaining thereto, and all other laws which regulate employment in California or elsewhere; or any other federal, state or local laws whether based on statute, regulation or common law, providing recourse for alleged wrongful discharge, breach of contract, breach of the covenant of good faith and fair dealing, physical or personal injury, privacy, emotional distress, fraud, negligent misrepresentation, libel, slander, defamation, assault, battery, any other torts, and similar or related claims. However, nothing herein shall be construed as interfering with Executive’s right to the payments explicitly provided for herein, or to Executive’s right to ongoing wages and benefits during Executive’s continued employment with Company; and
(d)    Claims of any kind or nature, based on, arising from, or relating in any way to the alleged acts, errors or omissions of the Releasees that occurred at any time before the date when Executive signs this Agreement.    
3.2Exempted from Release. Specifically exempted from this Release are claims for workers’ compensation (other than California Labor Code Section 132a claims or any other workers’ compensation claims based on any alleged willfulness, malice or intentional conduct by the Releasees, which claims are expressly released by this Agreement) and any other claims that cannot be waived as a matter of law.
3.3Unknown Claims, Waiver of California Civil Code Section 1542. Except as otherwise set forth herein, Executive understands and expressly

3 of 13

agrees that this Agreement extends to all claims of every nature and kind, known or unknown, suspected or unsuspected, past, present, or future, arising from or attributable to any conduct of the Releasees, whether set forth in any complaint, claim or demand referred to in this Agreement or not, and that any and all rights granted to Executive under Section 1542 of the California Civil Code or any analogous state law or federal law or regulation, are expressly WAIVED. Section 1542 of the California Civil Code reads as follows:
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR THE RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, AND THAT IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.
In waiving the provisions of Section 1542 of the California Civil Code, Executive acknowledges he may later discover facts in addition to or different from those he now believes to be true with respect to the matters released in this Agreement. Executive, however, agrees he has taken that possibility into account in reaching this Agreement, and that the release in this Agreement will remain in effect as a full and complete release notwithstanding the discovery or existence of additional or different facts.
3.4Consistent with the provisions of federal and state discrimination laws, nothing in this release shall be deemed to prohibit Executive from challenging the validity of this release under such discrimination laws (the “Discrimination Laws”) or from filing a charge or complaint of employment related discrimination with the Equal Employment Opportunity Commission (“EEOC”) or state equivalent, or from participating in any investigation or proceeding conducted by the EEOC the National Labor Relations Board, or state equivalent. Further, nothing in this release or Agreement shall be deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that Executive’s signing of this Agreement constitutes a full release of any individual rights under the Discrimination Laws, or to seek restitution to the extent permitted by law of the economic benefits provided to Executive under this Agreement in the event that Executive successfully challenges the validity of this release and prevails in any claim under the Discrimination Laws.
3.5Separation of Employment. In accordance with the terms of this Agreement and subject to Executive’s execution and compliance with the terms of this Agreement, Executive’s employment with the Company will end on the Separation Date. Executive acknowledges that

4 of 13

from and after the Separation Date, Executive shall have no authority to, and shall not represent himself as an employee of the Company.
3.6Non-Admission of Liability. By providing Executive with the benefits set forth in this Agreement, Company is not admitting that it or anyone else has done anything wrong. Executive agrees that this Agreement shall not be admissible in any court or other forum for any purpose other than for the enforcement of its terms.
3.7Right to Release. Executive represents, warrants, and agrees that: (a) he is the sole and lawful owner of all rights, title, and interest in and to every claim or matter which he intends to release in this Agreement, and which are in fact released in this Agreement; (b) he has not assigned or transferred to any person or entity any claim or other matter released in this Agreement; and (c) the making or performance of this Agreement will not violate any provision of law or obligation he may have to other persons or entities.
3.8Authorized to Execute. The undersigned represent that each is competent to execute this Agreement and are duly authorized, and have the full right and authority, to execute this Agreement on behalf of the Party for whom they are signing.
3.9Knowing and Voluntary Execution. Each Party acknowledges and represents that he or it: (a) has fully and carefully read the Agreement prior to execution; (b) has been fully apprised by his or its attorneys of the legal effect and meaning of this Agreement or has had the opportunity to review and address this Agreement with an attorney; (c) has had the opportunity to make whatever investigation or inquiry he or it deems necessary or appropriate in connection with the subject matter of this Agreement; (d) has been afforded the opportunity to negotiate any and all terms of this Agreement; and (e) is executing the Agreement voluntarily, free from any undue influence, coercion, or duress.
3.10Entire Agreement. The Supplemental Release, if executed, is expressly incorporated into, and shall be considered as part of, this Agreement. Each Party represents, warrants, and agrees that this Agreement contains the entire agreement between the Parties, that the Agreement supersedes any and all prior agreements or understandings between the Parties (with the exception of any confidentiality agreements and/or assignment of invention agreements entered into by Executive in connection with his work with Company and with the exception of the Employment Agreement except as herein expressly so amended), whether written or oral; that the terms of this Agreement are contractual and not a mere recital; and that in executing this Agreement, neither Company nor Executive is relying on any statement or representation made by the other, or any agents or attorneys of the other, concerning the subject

5 of 13

matter, basis or effect of this Agreement other than as set forth in this Agreement.
3.11Confidentiality. Executive agrees that the existence of this Agreement, the terms of this Agreement, and the information that forms the basis of this Agreement, including but not limited to any underlying claims by Executive, must be held in strictest confidence by Executive and must not be publicized or disclosed in any manner whatsoever; provided, however, that Executive may: (a) disclose this Agreement and/or its terms in confidence to his family (provided his family agrees in advance to keep the terms of this Agreement confidential); (b) disclose this Agreement in confidence to his attorneys, financial advisors, and/or tax advisors or accountants; and (c) disclose this Agreement to the extent necessary to enforce its terms or as otherwise required by law. Executive, for himself and on behalf of his agents and attorneys, acknowledges and agrees that a material term of this Agreement is that its terms and conditions are strictly confidential, subject to the limitations described above, and promises that he will not hereinafter discuss, describe, or in any other manner communicate the terms, conditions, or contents of this Agreement, including its existence and the negotiations leading thereto, directly or indirectly, or by or through any agent or attorney, to any source, individual, or entity. In response to any inquiry from third parties about this matter, Executive can respond by stating that “I have decided to resign from the company and/or retire” or words to that effect. Executive acknowledges and Company agrees that Executive may disclose confidential information in confidence directly or indirectly to federal, state, or local government officials to the extent expressly authorized under applicable law. Nothing in this Agreement is intended to conflict with federal law protecting confidential disclosures of a trade secret to the government or in a court filing, 18 U.S.C. § 1833(b), or to create liability for disclosures of confidential information that are expressly allowed by 18 U.S.C. § 1833(b).
3.12Non-Disparagement. Executive agrees not to and never to disparage Company or Company’s subsidiaries, parents, predecessors, employees, affiliates, and/or divisions, and their respective insurers, reinsurers, employees, officers, shareholders, owners, or directors or any of the persons or entities released under this Agreement, in any manner likely to be harmful to them or their business, business reputation, or personal reputation; provided that Executive may respond accurately and fully to any question, inquiry or request for information when required to do so by legal process. Executive agrees to direct all requests for references and employment verification from Company to Company’s Human Resources Department, which, apart from disclosures required by law, will only confirm to said requestors dates of employment and positions held, and if authorized in writing by Executive, his final compensation information at Company.

6 of 13

3.13Binding Effect. The Parties understand and expressly agree that this Agreement binds and benefits (as applicable) their respective heirs, assigns, successors, predecessors, agents, attorneys, representatives, employees, owners, officers, directors, partners, shareholders, subsidiaries, and affiliates.

4.OTHER TERMS AND CONDITIONS
4.1Voluntariness. By signing below, Executive acknowledges that he has been given twenty-one (21) days to consider whether or not to sign this Agreement and he has been advised in writing to consult with an attorney before signing it. Executive acknowledges that he understands that he may take as much of this 21-day period of time as he wishes to consider this Agreement before signing it.
4.2Revocability. Executive can revoke his acceptance of this Agreement within seven (7) days after signing this Agreement and this Agreement will not become effective until the end of that seven (7) day revocation period; therefore, this Agreement will become effective on the eighth (8th) day after Executive has signed and provided the Agreement to Company, and has not revoked this Agreement (the “Effective Date”). Revocation can be made by delivering a written notice of revocation by fax, electronic mail, or hand delivery to the attention of Alexander Fitzpatrick, General Counsel Evofem Biosciences, Inc. 12400 High Bluff Drive, Suite 600, San Diego, CA 92130 or at aftizpatrick@evofem.com as provided for in Section 4.3 below. For such revocation to be effective, written notice must be received no later than on the seventh day after Executive signs this Agreement.
4.3Notice. All notices, requests, demands and other communications hereunder shall be in writing and shall be delivered, either by hand, by overnight courier or by certified mail, return receipt requested, duly addressed as indicated below or to such changed address as may be subsequently designated:

To Company:         Alexander Fitzpatrick
General Counsel
Evofem Biosciences, Inc.
12400 High Bluff Drive, Suite 600
San Diego, California 92130
afitzpatrick@evofem.com
To Executive:        Russell Barrans

7 of 13

4.4Amendment and Modification. No amendment, modification, addendum, or revision of this Agreement will be valid or enforceable unless it is in writing and signed by each of the Parties.
4.5Waiver. No waiver or indulgence of any breach of this Agreement will be construed as a waiver of any other breach of the same or any other provision of this Agreement or affect the enforceability of any part of this Agreement. No waiver of the terms of this Agreement or waiver of the breach of the terms of this Agreement will be valid or enforceable unless executed in writing by the waiving Party.
4.6Attorneys’ Fees. Each Party agrees to bear his or its own costs, expenses and attorneys’ fees (as applicable) with respect to the matters released in this Agreement, and the negotiation and drafting of this Agreement.
4.7Counterparts. This Agreement may be signed in counterparts, facsimile copy and/or other electronically transmitted signatures, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.
4.8Construing Ambiguities. Each Party, with the opportunity to seek the assistance of competent counsel, participated in the drafting of this Agreement and therefore any ambiguities should not be construed for or against any Party on account of this drafting.
4.9Severability. If any provision of this Agreement is found to be unenforceable, it will not affect the enforceability of the remaining provisions and the courts may enforce all remaining provisions to the extent permitted by law.
4.10Governing Law; Venue. This Agreement or any disputes or claims arising from or relating to this Agreement must be governed by California law, irrespective of choice of law rules. Any lawsuit or claim relating to this Agreement must be filed in a federal or state court, as applicable, in San Diego County, California. The Parties expressly consent to the personal jurisdiction of the state and federal courts located in San Diego County, California, for any lawsuit filed there arising from or related to this Agreement.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY BLANK]

8 of 13

PLEASE READ CAREFULLY. THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.
IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives.

EVOFEM BIOSCIENCES, INC.
Dated: 11/12/2021 /s/ Saundra Pelletier
By: Saundra Pelletier
Its: CEO
Dated: 11/12/2021

/s/ Russell Barrans
RUSSELL BARRANS

9 of 13


EXHIBIT A
SUPPLEMENTAL RELEASE OF CLAIMS
I, Russell Barrans, hereby furnish Evofem Biosciences, Inc. (the “Company”) with this Supplemental Release of Claims (“Supplemental Release”) in consideration of the Confidential Employment Transition Plan and General Release Agreement (the “Agreement”).
1.I waive my right to assert any and all claims, demands, arbitrations, actions, suits, orders, proceedings, damages, debts, liabilities, obligations, remedies (including statutory remedies), wages, benefits, penalties, existing and future liens, and causes of action of every kind and nature, whether known or unknown, suspected or unsuspected, anticipated or unanticipated (the “Claims”) against Evofem Biosciences, Inc. and its successors, subsidiaries, parents, predecessors, affiliates, and divisions, and their respective insurers, reinsurers, shareholders, owners, employees, officers, directors, assigns, agents, representatives and attorneys (collectively, the “Releasees”) arising from the beginning of time through the date of the execution of this Supplemental Release (the “Supplemental Release Execution Date”). Except as set forth below, my waiver and release herein is intended to bar any and all Claims, including without limitation:
(a)That were or could have been alleged with respect to any aspect of my work at Company or with respect to any interactions between me and my co-workers and supervisors that occurred as of the Supplemental Release Execution Date;
(b)    That were, or could have, been based on, arising from, or relating in any way to any anti-discrimination statutes, such as Title VII of the Civil Rights Act of 1964, which prohibits race, color, religion, sex and national origin discrimination in employment; the California Fair Employment and Housing Act, which prohibits race, color, religion, sex, age, disability and national origin discrimination; the Americans With Disabilities Act, which prohibits discrimination against individuals with disabilities; the Family and Medical Leave Act, which prohibits discrimination based against individuals needing family or medical leave; the California Family Rights Act, which prohibits discrimination against individuals needing family or medical leave; the Age Discrimination in Employment Act, the Genetic Information Nondiscrimination Act of 2008, the Family and Medical Leave Act of 1993, the Employee Retirement Income Security Act of 1974, the Consolidated Omnibus Budget Reconciliation Act, and any similar California or other state or local statute or ordinance;

10 of 13

(c)    That were, or could have been, based on, arising from, or relating in any way to any other laws such as the California Labor Code and the Fair Labor Standards Act, which regulate wages, hours and working conditions, including but not limited to any and all claims for alleged failure to provide commissions and/or bonus, and any and all related penalties and interest pertaining thereto, and all other laws which regulate employment in California or elsewhere; or any other federal, state or local laws whether based on statute, regulation or common law, providing recourse for alleged wrongful discharge, breach of contract, breach of the covenant of good faith and fair dealing, physical or personal injury, privacy, emotional distress, fraud, negligent misrepresentation, libel, slander, defamation, assault, battery, any other torts, and similar or related claims. However, nothing herein shall be construed as interfering with my right to the payments explicitly provided for herein, or to my right to ongoing wages and benefits during my employment with Company; and
(d)    Claims of any kind or nature, based on, arising from, or relating in any way to the alleged acts, errors or omissions of the Releasees that occurred at any time before the Supplemental Release Execution Date.    

2.Except as otherwise set forth herein, I understand and expressly agree that this Supplemental Release extends to all claims of every nature and kind, known or unknown, suspected or unsuspected, past, present, or future, arising from or attributable to any conduct of the Releasees, whether set forth in any complaint, claim or demand referred to in this Agreement or not, and that any and all rights granted to me under Section 1542 of the California Civil Code or any analogous state law or federal law or regulation, are expressly WAIVED. Section 1542 of the California Civil Code reads as follows:
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR THE RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, AND THAT IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.
In waiving the provisions of Section 1542 of the California Civil Code, I acknowledge I may later discover facts in addition to or different from those I now believe to be true with respect to the matters released in this Supplemental Release. I, however, agree I have taken that possibility into account in executing this Supplemental Release, and that this Supplemental Release will remain in effect as a full and complete release notwithstanding the discovery or existence of additional or different facts.

11 of 13


3.Notwithstanding the foregoing, this Section does not release the Company from any obligation expressly set forth in this Supplemental Release or the Agreement. Further, my waivers and releases in this Supplemental Release do not apply to any claims that cannot be waived or released as a matter of law under applicable, federal, state, or local laws, including without limitation claims for workers’ compensation (other than California Labor Code Section 132a claims or any other workers’ compensation claims based on any alleged willfulness, malice or intentional conduct by the Releasees, which claims are expressly released by this Agreement). However, I acknowledge and agree that I do not have any work-related injuries or occupational diseases. I acknowledge and agree that, but for providing this waiver and release in the Supplemental Release, I would not be receiving the economic benefits being provided to me under the terms of Section 2.2 of the Agreement.
4.Consistent with the provisions of federal and state discrimination laws, nothing in this release shall be deemed to prohibit me from challenging the validity of this release under such discrimination laws (the “Discrimination Laws”) or from filing a charge or complaint of age or other employment related discrimination with the Equal Employment Opportunity Commission (“EEOC”) or state equivalent, or from participating in any investigation or proceeding conducted by the EEOC or state equivalent. Further, nothing in this Supplemental Release or the Agreement shall be deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that my signing of this Supplemental Release constitutes a full release of any individual rights under the Discrimination Laws, or to seek restitution to the extent permitted by law of the economic benefits provided to me under this Supplemental Release in the event that I successfully challenge the validity of this release and prevail in any claim under the Discrimination Laws.
5.By signing below, I acknowledge that I have been given twenty-one (21) days to consider whether or not to sign this Supplemental Release and I have been advised in writing to consult with an attorney before signing it. I acknowledge that I understand that I may take as much of this 21-day period of time as I wish to consider this Supplemental Release before signing it.
6.I can revoke my acceptance of this Agreement within seven (7) days after signing this Supplemental Release and this Supplemental Release will not become effective until the end of that seven (7) day revocation period; therefore, this Supplemental Release will become effective on the eighth (8th) day after I have signed and provided the Supplemental Release to Company, and have not revoked this Agreement. Revocation can be made by delivering a written notice of revocation by fax, electronic mail, or hand delivery to the attention of Alexander Fitzpatrick, General Counsel, Evofem Biosciences, Inc. 12400 High Bluff Drive, Suite 600, San Diego, CA 92130 or at afitzpatrick@evofem.com. For such revocation to be effective, I understand that my written notice must be received no later than the seventh day after I sign this Supplemental Release.

12 of 13

7.I represent, warrant, and agree that: (a) I am the sole and lawful owner of all rights, title, and interest in and to every claim or matter which I intend to release in this Supplemental Release, and which are in fact released in this Supplemental Release; (b) I have not assigned or transferred to any person or entity any claim or other matter released in this Supplemental Release; and (c) the making or performance of this Supplemental Release will not violate any provision of law or obligation I may have to other persons or entities.
By executing this Supplemental Release, I am acknowledging that: (1) I have carefully read and understand the terms and effects of this Supplemental Release, including my release of claims; (2) I understand that my release of claims is legally binding and by signing this Supplemental Release, I give up certain rights; (3) I have been afforded sufficient time to understand the terms and effects of this Supplemental Release; (4) my agreements and obligations hereunder are made voluntarily, knowingly and without duress; and (5) neither the Company nor its agents or representatives have made any representations inconsistent with the provisions of this Supplemental Release.
I understand and agree that all capitalized terms that are not defined in this Supplemental Release shall have the definitions provided to them in the Agreement. I also reaffirm my agreement and compliance with all of the terms set forth in the Agreement.

Date: 11/12/2021 By:

/s/ Russell Barrans
RUSSELL BARRANS

13 of 13

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Saundra Pelletier, certify that:
1 I have reviewed this quarterly report on Form 10-Q of Evofem Biosciences, Inc.;
 
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4 The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5 The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 


  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date: November 15, 2021 By:   /s/ Saundra Pelletier
    Saundra Pelletier
President and Chief Executive Officer
(principal executive officer)
 



Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Justin J. File, certify that:
1 I have reviewed this quarterly report on Form 10-Q of Evofem Biosciences, Inc.;
 
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4 The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5 The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 


  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 15, 2021 By: /s/ Justin J. File
    Justin J. File
Chief Financial Officer
(principal financial officer and principal accounting officer)

 



Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Evofem Biosciences, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), each of the undersigned officers of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of such officer’s knowledge:
  (1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
  (2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: November 15, 2021 By:   /s/ Saundra Pelletier
    Saundra Pelletier
President and Chief Executive Officer
(principal executive officer)
Date: November 15, 2021 By: /s/ Justin J. File
    Justin J. File
Chief Financial Officer
(principal financial officer and principal accounting officer)


 
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Evofem Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.